IE83824B1 - A selectin ligand - Google Patents
A selectin ligandInfo
- Publication number
- IE83824B1 IE83824B1 IE1992/1450A IE921450A IE83824B1 IE 83824 B1 IE83824 B1 IE 83824B1 IE 1992/1450 A IE1992/1450 A IE 1992/1450A IE 921450 A IE921450 A IE 921450A IE 83824 B1 IE83824 B1 IE 83824B1
- Authority
- IE
- Ireland
- Prior art keywords
- selectin
- ligand
- dna
- amino acid
- protein
- Prior art date
Links
- 230000027455 binding Effects 0.000 title claims description 246
- 239000003446 ligand Substances 0.000 title claims description 213
- 102000003800 Selectins Human genes 0.000 title claims description 107
- 108090000184 Selectins Proteins 0.000 title claims description 107
- AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 title claims description 94
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims description 109
- 210000004027 cells Anatomy 0.000 claims description 100
- 102000004169 proteins and genes Human genes 0.000 claims description 88
- 108090000623 proteins and genes Proteins 0.000 claims description 88
- 102000016551 L-Selectin Human genes 0.000 claims description 76
- 108010092694 L-Selectin Proteins 0.000 claims description 76
- 150000001413 amino acids Chemical class 0.000 claims description 53
- 102000004965 antibodies Human genes 0.000 claims description 50
- 108090001123 antibodies Proteins 0.000 claims description 50
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 48
- 229920001184 polypeptide Polymers 0.000 claims description 44
- 229920001850 Nucleic acid sequence Polymers 0.000 claims description 43
- 150000007523 nucleic acids Chemical class 0.000 claims description 34
- 229920002676 Complementary DNA Polymers 0.000 claims description 31
- 239000002299 complementary DNA Substances 0.000 claims description 29
- 108020004707 nucleic acids Proteins 0.000 claims description 29
- 230000014509 gene expression Effects 0.000 claims description 25
- 102000003886 Glycoproteins Human genes 0.000 claims description 22
- 108090000288 Glycoproteins Proteins 0.000 claims description 22
- 230000000875 corresponding Effects 0.000 claims description 17
- 102000018358 Immunoglobulins Human genes 0.000 claims description 16
- 108060003951 Immunoglobulins Proteins 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 15
- 241000282414 Homo sapiens Species 0.000 claims description 13
- 230000003511 endothelial Effects 0.000 claims description 12
- 241000894007 species Species 0.000 claims description 12
- 210000000265 Leukocytes Anatomy 0.000 claims description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 10
- 229920001405 Coding region Polymers 0.000 claims description 9
- 210000002889 Endothelial Cells Anatomy 0.000 claims description 9
- 230000000295 complement Effects 0.000 claims description 9
- 239000001963 growth media Substances 0.000 claims description 9
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 9
- 239000011780 sodium chloride Substances 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 210000003292 kidney cell Anatomy 0.000 claims description 5
- 230000000903 blocking Effects 0.000 claims description 4
- 108060000679 ATG12 Proteins 0.000 claims description 3
- 241000972773 Aulopiformes Species 0.000 claims description 3
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K Trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 235000019515 salmon Nutrition 0.000 claims description 3
- 239000001488 sodium phosphate Substances 0.000 claims description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 3
- 239000011778 trisodium citrate Substances 0.000 claims description 3
- 229940038773 trisodium citrate Drugs 0.000 claims description 3
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 3
- 101700045840 ECT Proteins 0.000 claims description 2
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 2
- 210000004962 mammalian cells Anatomy 0.000 claims description 2
- 230000003000 nontoxic Effects 0.000 claims description 2
- 231100000252 nontoxic Toxicity 0.000 claims description 2
- 239000000546 pharmaceutic aid Substances 0.000 claims description 2
- 108020001775 protein parts Proteins 0.000 claims description 2
- 230000003110 anti-inflammatory Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 101700079891 lgg-2 Proteins 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 82
- 235000001014 amino acid Nutrition 0.000 description 55
- 210000001165 Lymph Nodes Anatomy 0.000 description 33
- 239000011324 bead Substances 0.000 description 32
- 238000000034 method Methods 0.000 description 24
- 230000002093 peripheral Effects 0.000 description 21
- 238000000746 purification Methods 0.000 description 21
- 229920000272 Oligonucleotide Polymers 0.000 description 20
- 150000001720 carbohydrates Chemical class 0.000 description 19
- 235000014633 carbohydrates Nutrition 0.000 description 19
- 102000004419 dihydrofolate reductase family Human genes 0.000 description 19
- 108020001096 dihydrofolate reductase family Proteins 0.000 description 19
- 239000000463 material Substances 0.000 description 19
- 102000004190 Enzymes Human genes 0.000 description 18
- 108090000790 Enzymes Proteins 0.000 description 18
- 210000004698 Lymphocytes Anatomy 0.000 description 18
- 101700021338 LEC Proteins 0.000 description 16
- 101700077545 LECC Proteins 0.000 description 16
- 101700028499 LECG Proteins 0.000 description 16
- 101700063913 LECT Proteins 0.000 description 16
- 101710034340 Os04g0173800 Proteins 0.000 description 16
- 241000156302 Porcine hemagglutinating encephalomyelitis virus Species 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 239000000499 gel Substances 0.000 description 16
- 101700036391 lecA Proteins 0.000 description 16
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 15
- 102000005962 receptors Human genes 0.000 description 15
- 108020003175 receptors Proteins 0.000 description 15
- 101710015954 HVA1 Proteins 0.000 description 14
- 101700065814 LEA2 Proteins 0.000 description 14
- 239000002523 lectin Substances 0.000 description 14
- 101700001016 mbhA Proteins 0.000 description 14
- 108010045030 monoclonal antibodies Proteins 0.000 description 14
- 108020004999 Messenger RNA Proteins 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 13
- 229920002106 messenger RNA Polymers 0.000 description 13
- 102000005614 monoclonal antibodies Human genes 0.000 description 13
- 230000035772 mutation Effects 0.000 description 13
- 210000000056 organs Anatomy 0.000 description 13
- 239000002953 phosphate buffered saline Substances 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 230000003899 glycosylation Effects 0.000 description 12
- 238000006206 glycosylation reaction Methods 0.000 description 12
- 239000002609 media Substances 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- 229920000936 Agarose Polymers 0.000 description 11
- 238000004166 bioassay Methods 0.000 description 11
- 239000012528 membrane Substances 0.000 description 11
- 238000006467 substitution reaction Methods 0.000 description 11
- 229940088598 Enzyme Drugs 0.000 description 10
- 238000009396 hybridization Methods 0.000 description 10
- 238000001114 immunoprecipitation Methods 0.000 description 10
- 238000003780 insertion Methods 0.000 description 10
- 238000002703 mutagenesis Methods 0.000 description 10
- 231100000350 mutagenesis Toxicity 0.000 description 10
- 108091007521 restriction endonucleases Proteins 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 9
- 210000004408 Hybridomas Anatomy 0.000 description 9
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 9
- 230000001809 detectable Effects 0.000 description 9
- 230000029087 digestion Effects 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 239000003981 vehicle Substances 0.000 description 9
- IQFYYKKMVGJFEH-XLPZGREQSA-N DEOXYTHYMIDINE Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 8
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical group C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 8
- 210000002381 Plasma Anatomy 0.000 description 8
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 8
- 125000000837 carbohydrate group Chemical group 0.000 description 8
- 230000003993 interaction Effects 0.000 description 8
- 229960000060 monoclonal antibodies Drugs 0.000 description 8
- 102000015689 E-Selectin Human genes 0.000 description 7
- 108010024212 E-Selectin Proteins 0.000 description 7
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 7
- 102000003960 Ligases Human genes 0.000 description 7
- 108090000364 Ligases Proteins 0.000 description 7
- 102100003519 SELP Human genes 0.000 description 7
- 239000004473 Threonine Substances 0.000 description 7
- 239000003636 conditioned culture media Substances 0.000 description 7
- 229960000485 methotrexate Drugs 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- 238000001556 precipitation Methods 0.000 description 7
- 125000003616 serine group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 7
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 7
- 210000001519 tissues Anatomy 0.000 description 7
- 102000004594 DNA Polymerase I Human genes 0.000 description 6
- 108010017826 DNA Polymerase I Proteins 0.000 description 6
- 101700033006 EGF Proteins 0.000 description 6
- 102100010813 EGF Human genes 0.000 description 6
- MTCFGRXMJLQNBG-REOHCLBHSA-N L-serine Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 6
- 230000000890 antigenic Effects 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 238000010367 cloning Methods 0.000 description 6
- 230000002708 enhancing Effects 0.000 description 6
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 6
- DGVVWUTYPXICAM-UHFFFAOYSA-N 2-mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 5
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 5
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 5
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 5
- SHZGCJCMOBCMKK-DHVFOXMCSA-N Fucose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 210000003734 Kidney Anatomy 0.000 description 5
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 5
- 210000004185 Liver Anatomy 0.000 description 5
- 108010063954 Mucins Proteins 0.000 description 5
- 102000015728 Mucins Human genes 0.000 description 5
- 238000000636 Northern blotting Methods 0.000 description 5
- 102100003618 PLN Human genes 0.000 description 5
- 210000001986 Peyer's Patches Anatomy 0.000 description 5
- 239000000853 adhesive Substances 0.000 description 5
- 230000001070 adhesive Effects 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 239000012491 analyte Substances 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 239000006166 lysate Substances 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000006011 modification reaction Methods 0.000 description 5
- 229920002401 polyacrylamide Polymers 0.000 description 5
- -1 sialic acid Chemical compound 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 230000001131 transforming Effects 0.000 description 5
- 101700011961 DPOM Proteins 0.000 description 4
- 108010042407 Endonucleases Proteins 0.000 description 4
- 229940116977 Epidermal Growth Factor Drugs 0.000 description 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N Hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 4
- 102100005410 LINE-1 retrotransposable element ORF2 protein Human genes 0.000 description 4
- 210000004072 Lung Anatomy 0.000 description 4
- 210000003563 Lymphoid Tissue Anatomy 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- 101710029649 MDV043 Proteins 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 108010035766 P-Selectin Proteins 0.000 description 4
- 101700061424 POLB Proteins 0.000 description 4
- 229960005190 Phenylalanine Drugs 0.000 description 4
- 101700054624 RF1 Proteins 0.000 description 4
- 229940104230 Thymidine Drugs 0.000 description 4
- 210000000264 Venules Anatomy 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 230000002759 chromosomal Effects 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 239000005547 deoxyribonucleotide Substances 0.000 description 4
- 230000001419 dependent Effects 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000002209 hydrophobic Effects 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 230000001404 mediated Effects 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 230000032258 transport Effects 0.000 description 4
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 3
- 229960003767 Alanine Drugs 0.000 description 3
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 3
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 3
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 3
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- 210000000349 Chromosomes Anatomy 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 210000002472 Endoplasmic Reticulum Anatomy 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 229960002449 Glycine Drugs 0.000 description 3
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 229920001681 Heteroduplex Polymers 0.000 description 3
- 229960000310 ISOLEUCINE Drugs 0.000 description 3
- 210000000987 Immune System Anatomy 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-Acetylglucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 3
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 3
- 210000000440 Neutrophils Anatomy 0.000 description 3
- 108091005503 Nucleic proteins Proteins 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 101700009186 SELP Proteins 0.000 description 3
- 210000002966 Serum Anatomy 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 210000000952 Spleen Anatomy 0.000 description 3
- 210000001541 Thymus Gland Anatomy 0.000 description 3
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000000692 anti-sense Effects 0.000 description 3
- 102000038129 antigens Human genes 0.000 description 3
- 108091007172 antigens Proteins 0.000 description 3
- 230000003115 biocidal Effects 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000021164 cell adhesion Effects 0.000 description 3
- 239000006143 cell culture media Substances 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000000727 fraction Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000002055 immunohistochemical Effects 0.000 description 3
- 239000012133 immunoprecipitate Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229940079866 intestinal antibiotics Drugs 0.000 description 3
- 229960003136 leucine Drugs 0.000 description 3
- 101710030587 ligN Proteins 0.000 description 3
- 101700077585 ligd Proteins 0.000 description 3
- 239000003607 modifier Substances 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 230000004481 post-translational protein modification Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- 230000001105 regulatory Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000003248 secreting Effects 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 239000001226 triphosphate Substances 0.000 description 3
- 235000011178 triphosphate Nutrition 0.000 description 3
- 229960004295 valine Drugs 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- UCSJYZPVAKXKNQ-HZYVHMACSA-N 1-[(1S,2R,3R,4S,5R,6R)-3-carbamimidamido-6-{[(2R,3R,4R,5S)-3-{[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy}-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy}-2,4,5-trihydroxycyclohexyl]guanidine Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- OSJPPGNTCRNQQC-UWTATZPHSA-N 3-Phosphoglyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 2
- OIRDTQYFTABQOQ-GAWUUDPSSA-N 9-β-D-XYLOFURANOSYL-ADENINE Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@H](O)[C@H]1O OIRDTQYFTABQOQ-GAWUUDPSSA-N 0.000 description 2
- 101710026914 AAG Proteins 0.000 description 2
- 101710027066 ALB Proteins 0.000 description 2
- 102100001249 ALB Human genes 0.000 description 2
- 102000013563 Acid Phosphatase Human genes 0.000 description 2
- 108010051457 Acid Phosphatase Proteins 0.000 description 2
- OIRDTQYFTABQOQ-SXVXDFOESA-N Adenosine Natural products Nc1ncnc2c1ncn2[C@@H]3O[C@@H](CO)[C@H](O)[C@@H]3O OIRDTQYFTABQOQ-SXVXDFOESA-N 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 235000010751 Asperula odorata Nutrition 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
- 108010009575 CD55 Antigens Proteins 0.000 description 2
- 241001264766 Callistemon Species 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- 102000036640 Cullin Ring E3 Ligases Human genes 0.000 description 2
- 108091006941 Cullin Ring E3 Ligases Proteins 0.000 description 2
- ATDGTVJJHBUTRL-UHFFFAOYSA-N Cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 2
- GZCGUPFRVQAUEE-KCDKBNATSA-N D-(+)-Galactose Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-KCDKBNATSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- 229960000633 Dextran Sulfate Drugs 0.000 description 2
- 102000018251 EC 2.4.2.8 Human genes 0.000 description 2
- 108010091358 EC 2.4.2.8 Proteins 0.000 description 2
- 102000005731 EC 5.3.1.9 Human genes 0.000 description 2
- 108010070600 EC 5.3.1.9 Proteins 0.000 description 2
- 210000003038 Endothelium Anatomy 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 241000701533 Escherichia virus T4 Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 108060003339 GPLD1 Proteins 0.000 description 2
- 240000005071 Galium odoratum Species 0.000 description 2
- 235000008526 Galium odoratum Nutrition 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 229960002989 Glutamic Acid Drugs 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N HEPES Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 230000036499 Half live Effects 0.000 description 2
- 102000004851 Immunoglobulin G Human genes 0.000 description 2
- 108090001095 Immunoglobulin G Proteins 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 101700048515 LEC1 Proteins 0.000 description 2
- 101700046135 LEC2 Proteins 0.000 description 2
- 101700028593 LECH Proteins 0.000 description 2
- 101710024274 LGALS3BP Proteins 0.000 description 2
- 102100005731 LGALS3BP Human genes 0.000 description 2
- GUBGYTABKSRVRQ-YOLKTULGSA-N Maltose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@H]1CO)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 GUBGYTABKSRVRQ-YOLKTULGSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 2
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 2
- 229940051875 Mucins Drugs 0.000 description 2
- 210000000066 Myeloid Cells Anatomy 0.000 description 2
- 101700080605 NUC1 Proteins 0.000 description 2
- 108010006232 Neuraminidase Proteins 0.000 description 2
- 102000005348 Neuraminidase Human genes 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 229940092253 Ovalbumin Drugs 0.000 description 2
- 108010058846 Ovalbumin Proteins 0.000 description 2
- 210000001672 Ovary Anatomy 0.000 description 2
- AQSJGOWTSHOLKH-UHFFFAOYSA-N Phosphite Chemical compound [O-]P([O-])[O-] AQSJGOWTSHOLKH-UHFFFAOYSA-N 0.000 description 2
- DTBNBXWJWCWCIK-UHFFFAOYSA-N Phosphoenolpyruvic acid Natural products OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 description 2
- LLKYUHGUYSLMPA-UHFFFAOYSA-N Phosphoramidite Chemical compound NP([O-])[O-] LLKYUHGUYSLMPA-UHFFFAOYSA-N 0.000 description 2
- 229920001451 Polypropylene glycol Polymers 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 206010039073 Rheumatoid arthritis Diseases 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 241000311088 Schwanniomyces Species 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 102000004338 Transferrin Human genes 0.000 description 2
- 108090000901 Transferrin Proteins 0.000 description 2
- 240000008529 Triticum aestivum Species 0.000 description 2
- ZHSGGJXRNHWHRS-VIDYELAYSA-N Tunicamycin Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](O)[C@@H](CC(O)[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(NC(=O)C=C2)=O)O)O1)O)NC(=O)/C=C/CC(C)C)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O ZHSGGJXRNHWHRS-VIDYELAYSA-N 0.000 description 2
- 230000036462 Unbound Effects 0.000 description 2
- 240000004652 Vaccinium ovalifolium Species 0.000 description 2
- SRBFZHDQGSBBOR-SQOUGZDYSA-N Xylose Natural products O[C@@H]1CO[C@@H](O)[C@@H](O)[C@@H]1O SRBFZHDQGSBBOR-SQOUGZDYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 229960005305 adenosine Drugs 0.000 description 2
- 239000000910 agglutinin Substances 0.000 description 2
- 229940050528 albumin Drugs 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- 230000001580 bacterial Effects 0.000 description 2
- 244000052616 bacterial pathogens Species 0.000 description 2
- 230000001588 bifunctional Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L cacl2 Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 108091006028 chimera Proteins 0.000 description 2
- 230000002860 competitive Effects 0.000 description 2
- 230000001143 conditioned Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000001808 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000001086 cytosolic Effects 0.000 description 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
- 150000002019 disulfides Chemical group 0.000 description 2
- 229940079593 drugs Drugs 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000004407 endothelial cell of postcapillary venule of lymph node Anatomy 0.000 description 2
- 230000002255 enzymatic Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 150000002484 inorganic compounds Chemical class 0.000 description 2
- 229910010272 inorganic material Inorganic materials 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000000670 limiting Effects 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 101700006494 nucA Proteins 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 125000003835 nucleoside group Chemical group 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 238000002205 phenol-chloroform extraction Methods 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 150000003905 phosphatidylinositols Chemical class 0.000 description 2
- 230000001402 polyadenylating Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000001737 promoting Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 239000012581 transferrin Substances 0.000 description 2
- 108010087967 type I signal peptidase Proteins 0.000 description 2
- 238000004450 types of analysis Methods 0.000 description 2
- 235000021307 wheat Nutrition 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N α-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- PEGXWGRIMLVKFY-AKGZTFGVSA-N (2S)-4-amino-2-(2,3-dihydroxypropylamino)-4-oxobutanoic acid Chemical compound NC(=O)C[C@@H](C(O)=O)NCC(O)CO PEGXWGRIMLVKFY-AKGZTFGVSA-N 0.000 description 1
- KYBXNPIASYUWLN-WUCPZUCCSA-N (2S)-5-hydroxypyrrolidine-2-carboxylic acid Chemical compound OC1CC[C@@H](C(O)=O)N1 KYBXNPIASYUWLN-WUCPZUCCSA-N 0.000 description 1
- PNOCSDIJELBTOO-BHQNPOKRSA-D (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5R,6R)-3-acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2S,3R,4R,5R,6R)-3-acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2S,3R,4R,5R,6R)-3-acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2S,3R,4R,5R,6R)-3-acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5R,6R)-3-acetamid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O[C@H]8[C@@H]([C@@H](O[C@H]9[C@@H]([C@@H](O)[C@H](O)[C@H](O9)C([O-])=O)O)[C@@H](OS([O-])(=O)=O)[C@@H](CO)O8)NC(C)=O)[C@H](O7)C([O-])=O)O)[C@@H](OS([O-])(=O)=O)[C@@H](CO)O6)NC(C)=O)[C@H](O5)C([O-])=O)O)[C@@H](OS([O-])(=O)=O)[C@@H](CO)O4)NC(C)=O)[C@H](O3)C([O-])=O)O)[C@@H](OS([O-])(=O)=O)[C@@H](CO)O2)NC(C)=O)[C@@H](C([O-])=O)O1 PNOCSDIJELBTOO-BHQNPOKRSA-D 0.000 description 1
- 125000003287 1H-imidazol-4-ylmethyl group Chemical group [H]N1C([H])=NC(C([H])([H])[*])=C1[H] 0.000 description 1
- 150000003923 2,5-pyrrolediones Chemical class 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 125000000979 2-amino-2-oxoethyl group Chemical group [H]C([*])([H])C(=O)N([H])[H] 0.000 description 1
- 125000003974 3-carbamimidamidopropyl group Chemical group C(N)(=N)NCCC* 0.000 description 1
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- 229940117976 5-hydroxylysine Drugs 0.000 description 1
- 101700033661 ACTB Proteins 0.000 description 1
- 102100011550 ACTB Human genes 0.000 description 1
- 101710032514 ACTI Proteins 0.000 description 1
- 101700080270 ADH2 Proteins 0.000 description 1
- 101700012170 ADH5 Proteins 0.000 description 1
- 101700033574 ADH6 Proteins 0.000 description 1
- 102100013689 ALPI Human genes 0.000 description 1
- 101710032898 ALPI Proteins 0.000 description 1
- 229960003896 Aminopterin Drugs 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N Ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N Ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 229960001230 Asparagine Drugs 0.000 description 1
- 229960005261 Aspartic Acid Drugs 0.000 description 1
- 206010003816 Autoimmune disease Diseases 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 240000008371 Bacillus subtilis Species 0.000 description 1
- 229940075615 Bacillus subtilis Drugs 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 210000004369 Blood Anatomy 0.000 description 1
- 241000701922 Bovine parvovirus Species 0.000 description 1
- 210000004556 Brain Anatomy 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- OSNYMVWMPOZYSX-UHFFFAOYSA-M CSC(C([O-])=N)CC Chemical compound CSC(C([O-])=N)CC OSNYMVWMPOZYSX-UHFFFAOYSA-M 0.000 description 1
- 101710022848 CYPADH Proteins 0.000 description 1
- 241000466177 Cansumys canus Species 0.000 description 1
- 210000000170 Cell Membrane Anatomy 0.000 description 1
- 210000001638 Cerebellum Anatomy 0.000 description 1
- 210000004720 Cerebrum Anatomy 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 210000003917 Chromosomes, Human Anatomy 0.000 description 1
- 229920000062 Coding strand Polymers 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M Coomassie Brilliant Blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 241001362614 Crassa Species 0.000 description 1
- 210000000805 Cytoplasm Anatomy 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108060002292 DMBT1 Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 102000019622 EC 2.7.1.2 Human genes 0.000 description 1
- 108010021582 EC 2.7.1.2 Proteins 0.000 description 1
- 102000013009 EC 2.7.1.40 Human genes 0.000 description 1
- 108020005115 EC 2.7.1.40 Proteins 0.000 description 1
- 102000008422 EC 2.7.1.78 Human genes 0.000 description 1
- 108010021757 EC 2.7.1.78 Proteins 0.000 description 1
- 108010011939 EC 4.1.1.1 Proteins 0.000 description 1
- 102000012288 EC 4.2.1.11 Human genes 0.000 description 1
- 108010022181 EC 4.2.1.11 Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 241001524679 Escherichia virus M13 Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 229920000665 Exon Polymers 0.000 description 1
- 210000002744 Extracellular Matrix Anatomy 0.000 description 1
- 230000035693 Fab Effects 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 102100011343 GLB1 Human genes 0.000 description 1
- 102100011534 GLYCAM1 Human genes 0.000 description 1
- 101710017637 GLYCAM1 Proteins 0.000 description 1
- 102000006602 Glyceraldehyde-3-Phosphate Dehydrogenases Human genes 0.000 description 1
- 108020004445 Glyceraldehyde-3-Phosphate Dehydrogenases Proteins 0.000 description 1
- 229920002306 Glycocalyx Polymers 0.000 description 1
- 210000004517 Glycocalyx Anatomy 0.000 description 1
- 102000019483 Glycosyltransferases Human genes 0.000 description 1
- 108091022077 Glycosyltransferases Proteins 0.000 description 1
- 210000002288 Golgi Apparatus Anatomy 0.000 description 1
- WZUVPPKBWHMQCE-VYIIXAMBSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@@]2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-VYIIXAMBSA-N 0.000 description 1
- 206010073071 Hepatocellular carcinoma Diseases 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 108020002022 Hexokinases Proteins 0.000 description 1
- 102000005548 Hexokinases Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229940088597 Hormone Drugs 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 229960002591 Hydroxyproline Drugs 0.000 description 1
- 229940072221 IMMUNOGLOBULINS Drugs 0.000 description 1
- 229940027941 Immunoglobulin G Drugs 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 231100000608 Immunotoxin Toxicity 0.000 description 1
- 108010004484 Immunotoxins Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 229920002459 Intron Polymers 0.000 description 1
- 108020004391 Introns Proteins 0.000 description 1
- QWTDNUCVQCZILF-UHFFFAOYSA-N Isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 1
- YWXYYJSYQOXTPL-SLPGGIOYSA-N Isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
- KXCLCNHUUKTANI-RBIYJLQWSA-N Keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 1
- 229920000288 Keratan sulfate Polymers 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-2-aminohexanoic acid zwitterion Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- 101710010796 LYZ Proteins 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000010836 Lymphocyte Homing Receptors Human genes 0.000 description 1
- 108010037354 Lymphocyte Homing Receptors Proteins 0.000 description 1
- 239000004907 Macro-emulsion Substances 0.000 description 1
- 229920002521 Macromolecule Polymers 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- LUEWUZLMQUOBSB-GFVSVBBRSA-N Mannan Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-GFVSVBBRSA-N 0.000 description 1
- 230000036740 Metabolism Effects 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010086093 Mung Bean Nuclease Proteins 0.000 description 1
- 210000002027 Muscle, Skeletal Anatomy 0.000 description 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-ACETYL-D-GALACTOSAMINE Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
- 229950006780 N-Acetylglucosamine Drugs 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-hydroxy-Succinimide Chemical class ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000221960 Neurospora Species 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N Ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 210000004940 Nucleus Anatomy 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 229960003104 Ornithine Drugs 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 101710042135 PPi-PFK Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 229940055729 Papain Drugs 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 229940049954 Penicillin Drugs 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- 102000011755 Phosphoglycerate kinases Human genes 0.000 description 1
- 108020004454 Phosphoglycerate kinases Proteins 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 102000007584 Prealbumin Human genes 0.000 description 1
- 108010071690 Prealbumin Proteins 0.000 description 1
- 108010076181 Proinsulin Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 108020005067 RNA Splice Sites Proteins 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 239000007759 RPMI Media 1640 Substances 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N Rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 101710038665 SELE Proteins 0.000 description 1
- 101000022423 SELE Proteins 0.000 description 1
- 102100017511 SPN Human genes 0.000 description 1
- 101710018229 SPN Proteins 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010039447 Salmonellosis Diseases 0.000 description 1
- 229920000972 Sense strand Polymers 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 210000000717 Sertoli cell Anatomy 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 229920000978 Start codon Polymers 0.000 description 1
- 229960005322 Streptomycin Drugs 0.000 description 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 1
- 102100003095 TNFRSF1A Human genes 0.000 description 1
- 101710038526 TNFRSF1A Proteins 0.000 description 1
- 210000001550 Testis Anatomy 0.000 description 1
- 229960002180 Tetracycline Drugs 0.000 description 1
- OFVLGDICTFRJMM-WESIUVDSSA-N Tetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O OFVLGDICTFRJMM-WESIUVDSSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 230000036335 Tissue distribution Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N Trifluoromethanesulfonic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- 102000005924 Triose-phosphate isomerases Human genes 0.000 description 1
- 108020003073 Triose-phosphate isomerases Proteins 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229960003487 Xylose Drugs 0.000 description 1
- 230000002378 acidificating Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000002788 anti-peptide Effects 0.000 description 1
- 239000012223 aqueous fraction Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000000511 arginine group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay method Methods 0.000 description 1
- ZXVOCOLRQJZVBW-UHFFFAOYSA-O azanium;ethanol Chemical compound [NH4+].CCO ZXVOCOLRQJZVBW-UHFFFAOYSA-O 0.000 description 1
- 229960000626 benzylpenicillin Drugs 0.000 description 1
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 102000006635 beta-Lactamases Human genes 0.000 description 1
- 108020004256 beta-Lactamases Proteins 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 201000009030 carcinoma Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000024881 catalytic activity Effects 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 102000008395 cell adhesion mediator activity proteins Human genes 0.000 description 1
- 108040002558 cell adhesion mediator activity proteins Proteins 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic Effects 0.000 description 1
- 238000005354 coacervation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 238000010192 crystallographic characterization Methods 0.000 description 1
- 230000004059 degradation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003413 degradative Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000005014 ectopic expression Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- YNQLUTRBYVCPMQ-UHFFFAOYSA-N ethylbenzene Chemical compound CCC1=CC=CC=C1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037240 fusion proteins Human genes 0.000 description 1
- 230000002068 genetic Effects 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- 230000002414 glycolytic Effects 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000003054 hormonal Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000025970 human SELE protein Human genes 0.000 description 1
- 238000002169 hydrotherapy Methods 0.000 description 1
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 1
- 230000000640 hydroxylating Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 150000002463 imido esters Chemical class 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000000968 intestinal Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000001573 invertase Substances 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000000155 isotopic Effects 0.000 description 1
- 230000023404 leukocyte cell-cell adhesion Effects 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000001466 metabolic labeling Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000035786 metabolism Effects 0.000 description 1
- 125000001360 methionine group Chemical class N[C@@H](CCSC)C(=O)* 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 101700042127 nucS Proteins 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Polymers 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000036961 partial Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic Effects 0.000 description 1
- 230000001575 pathological Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 101710036149 pfk-1.2 Proteins 0.000 description 1
- 101700087004 pfkA1 Proteins 0.000 description 1
- 101700035696 pfkB Proteins 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000865 phosphorylative Effects 0.000 description 1
- 108091008117 polyclonal antibodies Proteins 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000000379 polymerizing Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propanol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000000734 protein sequencing Methods 0.000 description 1
- 210000001938 protoplasts Anatomy 0.000 description 1
- 201000004681 psoriasis Diseases 0.000 description 1
- 230000002285 radioactive Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000002829 reduced Effects 0.000 description 1
- 238000001226 reprecipitation Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 125000005629 sialic acid group Chemical group 0.000 description 1
- 125000005630 sialyl group Chemical group 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 108010012704 sulfated glycoprotein p50 Proteins 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival Effects 0.000 description 1
- 230000002194 synthesizing Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N trans-L-hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 230000002103 transcriptional Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- 210000004881 tumor cells Anatomy 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Description
PATENTS ACT, 1992
92/I450
A SELECTIN LIGAND
GENENTECH, INC.
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
i. E _qf_ _t_lE invention
The present invention relates to endothelial selectin ligands. The invention further
relates to methods and means for preparing and to nucleic acids encoding these ligands.
ll. Description g _an_d flfltegfl
Lymphocytes are mediators of normal tissue inflammation as well as pathologic tissue
damage such as occurs in rheumatoid arthritis and other autoimmune diseases. In order to
fully exploit the antigenic repertoire of the immune system, vertebrates have evolved a
mechanism for distributing lymphocytes with diverse antigenic specificities to spatially distinct
regions of the organism (Butcher, E.C., Curr. Top. Micro. lmmunol. _1__2_8_, 85 (1986); Gallatin
er a/., E 53, 673 (1986); Woodruff et a/., lmmunol. Today 19, 23 (1989); Yednock er a/.,
Adv. lmmunol._t}_t1, 313 (1989)].
This mechanism involves the continuous recirculation of the lymphocytes between the
blood, where the cells have the greatest degree of mobility, and the lymphoid organs, where
the lymphocytes encounter sequestered and processed antigen.
lymphocytes is dictated in large part by organ-specific binding of lymphocytes to HEV
[Butcher (1986), Sugra]. Operationally, the lymphocyte-associated molecules underlying the
organ-selective interaction with HEV are termed "homing receptors" while the cognate
endothelial molecules are known as "HEV ligands" (Gallatin et al. (1986), Sugra; Rosen, Curr.
Opin. Cell. Biol. 1, 913 (198911. The endothelial HEV ligands are postulated to be distinctive
for the different lymphoid organs and as such are proposed to be responsible for regulating
the lymphocyte populations to enter each class of lymphoid organ lButcher, Am. J. Pathol.
@, 3 (1990)). A characterization of the detailed molecular mechanisms underlying
lymphocyte trafficking is interesting from both a scientific and a clinical standpoint, since
similar adhesive processes may be involved in both the normal and pathogenic forms of
leukocyte inflammation [Watson et a/., big 14$, 164-167 (1991 )1.
Of the homing receptors, the most thoroughly studied is a receptor initially termed
peripheral lymph node homing receptor (pnHR). This receptor was first defined in the murine
system by the MEL-14 monoclonal antibody (mAb), an antibody that was found to recognize
an about 90 kD leukocyte surface antigen (referred to as gp90”‘“) [Gallatin et a/., mag,
(198311. This antibody was found to block the lymphocyte adhesion to HEV of peripheral
and mesenteric lymph nodes in the Stamper-Woodruff in vitro adherence assay and to prevent
in viva migration to lymph nodes. A homing function for gp90““ was definitely shown by
the finding that detergent solubilized and soluble recombinant forms of the receptor can
selectively block adhesive sites for lymphocytes on LN but not those on FF HEV [Geoffroy
and Rosen, J. Cell. Biol. _1__Qg, 2463 (198911.
Other researchers identified another molecule associated with neutrophil adhesion. It
was proposed that this molecule, termed the endothelial leukocyte adhesion molecule ELAM-
1, is an inducible adhesion molecule whose role may be to mediate the attachment of
neutrophils to venular endothelial cells adjacent to sites of inflammation lBevilacqua et al.,
Proc. Natl. Acad. Sci. USA Q, 9238 (1989); Hession et a/., Prgc. Natl; Ag_a_g. Sci. LJSA
discovery of a further adhesion molecule variously termed granular membrane protein—14O
lGMP-140), platelet activation dependent granule external membrane protein (PADGEM) or
CD62 [McEver et a/., J. Biol. Chem. _2;9_, 9799 (1984); Bonfanti at a/., _B|iog13_, 1109
(1989); Hattori et al., J. Biol. Chem. _2_6_4l14), 7768 l1989ll. The cDNA sequence encoding
this receptor was determined by Johnston et a/., Qlfi, 1033 (1989).
Comparison of their amino acid sequences revealed that these three adhesion
molecules are related in a highly striking and compelling manner. Their common mosaic
structure consists of a calcium dependent lectin or carbohydrate-binding motif, an epidermal
growth factor-like (EGF) motif, and variable numbers of a complement regulatory lCFll Tnotif.
The ordered conjunction of these motifs has given rise to the name LEC-CAM LLectin ggf
Complement regulatory-_C_el| Adhesion Molecule) for this new family of leukocyte endothelial
(1985): Rosen er al., ,l.:|rn_rr__igr1o_l. _1A_2_, 1895 (‘l989l]. Because this enzyme selectively
removes terminal sialic acid residues from oligosaccharides, these results strongly implied that
sialic acid was a critical element for recognition.
The nature of the endothelial moleculelsl recognized by L-selectin was subsequently
probed with a unique recombinant chimera, consisting of the extracellular domain of L-selectin
joined to the hinge, CH2 and CH3 regions of the human IgG1 heavy chain [see WO 91/08298
published 13 June 1991 for the chimera, and Watson er al., J. Cell gig]. _1_m, 2221 (1990)
for its use as aprobe for adhesive ligands of lymph node high endothelial venules]. Initial
studies with this so-called receptor-immunoglobulin chimera demonstrated that it could adhere
to la) peripheral and mesenteric lymph node-specific HEV ligandlsl in cell blocking and
immunohistochemical experiments [Watson at al. (1990), firm]. The immunohistochemical
recognition of this HEV ligand was abolished by treatment of lymph node sections with
sialidase, suggesting that a component of the carbohydrate recognized by L-selectin was
sialic acid-like and further accentuated the importance of the lectin domain in L—selectin-
mediated adhesion [Rosen er al., Science (Wash. D.C.)_2_2_8_, 1005-1007 (1985); Rosen er al.
(1989). £113, and True er al., 11, 2757-2764 l1990ll.
demonstrated the specificity of the L-selectin-immunoglobulin chimera for the pin HEV ligand
These results
and established that the ligand expresses carbohydrate residues that are essential for homing
receptor-mediated cell adhesion.
A recent series of publications confirmed that the E-selectin ligand also has a
carbohydrate character. Several laboratories, adopting a wide range of approaches, have
concluded that an E-selectin ligand is a carbohydrate known as sialyl Lewis‘ (sLexl or a
closely related structure known as CD65 or VIM-2 [NeuAca2-3Galb.1 -4(Fuca1-3)GlcNAcb1 I.
Lowe er a/.lC_el_| Q. 475 (l990)]. transfected non-myeloid cells with an a1,3/4
show inhibition of E-selectin dependent adhesion with either Slex-containing glycoconjugates
similarities in the ligands suggest that the ligands will have related and yet subtlely different
structures.
An object of the present invention is to provide a method for the purification of a
selectin ligand.
Another object of the invention is to provide purified selectin, specifically L~selectin
ligands.
A further object of the present invention is to provide nucleic acid sequences encoding
selectin glycoprotein ligands.
It is another object to determine the amino acid sequences of the selectin ligands, and
to identify the (O- and N-linked) glycosylation sites on these ligands.
A still further object is to enable the preparation of amino acid sequence and/or
glycosylation variants of selectin ligands, not otherwise found in nature.
In a still further aspect, the invention provides a method of designing selectin inhibitors,
mimicking carbohydrate based determinants of the selectin ligands.
SUMMARY OF THE INVENTION
Fucose, sulfate and slalic acid were found in the 0-linked chains of these molecules, and it
is believed that fucose, like sialic acid, is required for full ligand activity.
In order to further characterize the nature of the endothelial ligand recognized by L-
selectin, we have taken the novel approach of affinity purifying the sulfated ~50 kD HEV
glycoprotein with the L-selectin-lgG chimera. The purified glycoprotein has been subjected
to N-terminal amino acid sequencing, and this sequence information has been utilized to clone
a cDNA encoding the protein component of this L-selectin ligand. It has been found that the
cDNA encodes a novel, highly O-linked lmucin-like) glycoprotein that appears to function as
a scaffold that presents carbohydrates to the lectin domain of L-selectin. Details of the
experimental work along with the findings and their interpretation are provided in the
examples.
The present invention concerns an isolated nucleic acid molecule comprising a
nucleotide sequence encoding a selectin ligand as claimed in Claim 1.
Such nucleic acid molecule comprises a nucleotide sequence able to
hybridize to the complement of a nucleotide sequence encoding a protein having the amino
acid sequence shown in Figure 4.
in another embodiment, the nucleic acid molecule comprises a nucleotide sequence
encoding a selectin ligand protein having an amino acid sequence greater than about 40%
homologous with the amino acid sequence shown in Figure 4.
In a further embodiment, the nucleic acid molecule is selected from the group
consisting, of:
la) a cDNA clone having a nucleotide sequence derived from the coding region of
a native selectin ligand gene;
(b) a DNA sequence able to hybridize under low stringency conditions to a clone of
(a); and
(C) a genetic variant of any of the DNA sequences of la) and lb) which encodes a
glycoprotein possessing a biological property of a naturally occurring ligand of a selectin
molecule.
The nucleic acid molecule of the invention may further comprise a nucleotide sequence
encoding an immunoglobulin constant domain.
in another aspect, the present invention concerns an expression vehicle comprising
a nucleotide sequence of Claim 1, operably linked to control sequences recognized by a host
cell transformed with the vehicle.
in a further aspect, the invention relates to a host cell transformed with the above-
described expression vehicle, and methods for culturing such transformed host cells to
express a selectin ligand.
In a still further aspect, the present invention concerns an isolated L—selectin ligand
polypeptide according to claim 16.
Such polypeptide may comprise the extracellular region of an endothelial cell
surface glycoprotein. In another embodiment, the polypeptide is Sgp5O or Sgp90.
The polypeptide of the present invention preferably comprises an amino acid
sequence having a sterical structure allowing for the presentation of a L-selectin-binding
moiety to its receptor.
in a specific embodiment, the foregoing polypeptide comprises an amino acid
sequence encoded by a nucleic add able to hybridize under low stringency conditions to the
complement of a nucleotide sequence encoding the protein having the amino acid sequence
shown in Figure 4.
in a further specific embodiment, the above—described polypeptide is a native
selectin ligand substantially free of other proteins of the same animal species in which it
naturally occurs.
In a still further aspect, the invention concerns a polypeptide as hereinbefore
defined, further comprising an immunoglobulin constant domain sequence.
In a different aspect, the invention concerns a composition comprising an amount of
a L-selectin ligand polypeptide as hereinabove defined, effective in blocking the binding of a
corresponding selectin receptor to its native ligand, in admixture with a non—toxic,
pharmaceutically acceptable excipient.
In another aspect, the invention relates to the use of the L—selectin ligand
polypeptide in the treatment of a symptom or condition associated with excessive binding of
circulating leukocytes to endothelial cells.
In still another aspect, the invention concerns an antibody immunoreactive with the
protein part of the L—selectin ligand polypeptide. Preferred antibodies bind the respective
selectin ligand but will not substantially cross-react with any other known ligands, and will
prevent the selectin ligands from binding to their receptors. The anti—selectin ligand
antibodies may be immobilized, and in this form are, for example, useful for the detection or
purification of the selectin ligands of the present invention.
In a further aspect, the invention relates to a method for determining the presence of
a nucleotide sequence encoding the L—selectin ligand polypeptide, comprising
a) hybridizing a nucleic acid encoding (the protein having the amino acid sequence
shown in Figure 4) to a test sample of nucleic acid; and
b) detecting any hybridization to determine the presence of the nucleotide sequence
in the sample.
In a still further aspect, the invention provides a method for the purification of the L-
selectin ligand polypeptide comprising absorbing the ligand to a chimera comprising the
corresponding L—selectin and an immunoglobulin heavy chain sequence.
The invention further concerns a method for presenting a L—se|ectin—binding moiety
to a corresponding L—selectin by binding such moiety to the L—selectin ligand polypeptide.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 illustrates the structures of the selectin (LEC-CAM) family members as
determined by cDNA cloning. Illustrated are the structures for L-selectin, E-selectin and P-
selectin. The lectin, epidermal growth factor (EGF), and multiple short consensus repeats
(SCRs) are shown with hypothetical disulfide bond structures as first proposed for GMP—140
by Johnston et al., Cell 56, 1033 (1989). An N-terminal sequence is also shown
(subsequently cleaved in the mature protein) as well as a hydrophobic transmembrane
spanning anchor (TM) and cytoplasmic tail. Two other forms of P-selectin are also illustrated,
one with a deleted scr-7 domain and another with a deleted membrane spanning anchor.
Figure 2 shows the structure of the genes encoding members of the selectin family.
Illustrated are the genomic structures encoding both human and murine L-selectin, human E-
selectin and human P-selectin. The dark boxes show exons that encode the various structural
motifs, including the start codon for the murine gene (ATG), the signal sequence (SS), the
lectin (LEC), epidermal growth factor (E), short concensus repeats (SCR), transmembrane
anchor (TM) and cytoplasmic domains (CD) and the intervening regions encode the introns
that separate these protein coding domains. In the human, all three selectin genes are within
200 kilobases of each other on the long arm of chromosome 1 near a locus encoding a family
of proteins that all contain variable numbers of the short SCR exon. The murine L-selectin
is also encoded on murine chromosome 1 in a region syntonic to that found in the human
chromosome 1 homologue.
Figure 3A. Illustrates the purification and N-terminal amino acid sequence of the ~ 50
kD L—selectin ligand. The purification of ligand from conditioned medium was monitored by
following added “S-labeled ligand. Lane A, Starting conditioned medium. Lane B, Aqueous
layer after chloroform:methano| partitioning. Lane C, LEC-lgG bound material, the bracketed
area was cut out for gas-phase protein sequencing. Lanes A-C are ProBlott membrane
stained with Coomassie R-250. Lane D is the autoradiograph of Lane C.
Figure 3B. N-terminal amino acid sequence.
Figure 3C. The C-terminal 21 amino acids were analyzed by the wheel program. This
program displays a view down the barrel of a helical region and illustrates the amino acid
residues surrounding the helix. Apolar amino acids are shown in open boxes and polar amino
acids are shown in shaded boxes.
Figure 3D. Illustrates a hydropathy plot derived from the predicted amino acid
sequence in A. The dark balls correspond to serine or threonine residues, while the open ball
is the ASN of the single potential N-linked glycosylation site. The predicted domain structure
of the ~50 kD ligand is shown above, with the signal sequence (SS), O-linked regions I and
ll and the C-terminal amphipathic helical region.
Figure 4 shows the nucleotide and the encoded amino acid sequence of the core
protein of an endothelial ligand for L—selectin. The unshaded box illustrates a Kozak
translational initiation site surrounding the first methionine codon. The dotted underlined
amino acid sequence beginning at residue 20 corresponds with the amino acid sequence
determined by N—terminal sequencing of the L-selectin purified ligand (Figure 3B) with the
exception of a THR at position 34 (a MET in the N-terminal sequence). The serine and
threonine residues in the predicted amino acid sequence are shown in shaded boxes.
Figures 5A and 5B show the immunoprecipitation of the L-selectin purified ~50 kD
ligand by peptide antibodies. The codes for the legends of Figures 5A and 5B are:
.9.
P1 = Preimmune CAMO1 - beads
I31 = Preimmune CAMO1 - supernatent left after immunoprecipitation
ll Immune CAMOl - beads
ll
P32 = Preimmune CAM02 - supernatent left after immunoprecipitation
lmmune CAM01 - supernatant left after immunoprecipitation
I3 = immune CAM02 - supernatant left after immunoprecipitation
I2 = immune CAMO2 - beads
PEP = free peptide
Figure 6. Northern blot analysis of the expression of the mRNA encoding the -— 50 kD
L-selectin ligand. A. Totallal or poly A+ (b, c) RNA was isolated from normal la,bl or
inflamed lcl peripheral lymph nodes, run on formaldehyde gels and analyzed by Northern blot
analysis with the cDNA shown in Figure 4. B. Poly A + RNA was isolated from al brachial,
bl axillary, cl cervical, dl popliteal, and el total peripheral lymph node and hybridized on
Northern blots with the ligand cDNA as described in A., C. and D. Poly A + RNA was isolated
from al peripheral lymph nodes, bl liver, cl Peyer's patch, dl thymus, el skeletal muscle, f)
mesenteric lymph nodes, gl testes, hl lung, i) heart, jl spleen, kl brain, and ii kidney and
hybridized on Northern blots with C. the cDNA corresponding to the L-selectin ligand or D.
achicken beta actin cDNA.
Figure 7. lisjty hybridization analysis of the expression of the mRNA encoding the
~ 50 kD L-selectin ligand. Peripheral lymph node sections were hybridized with either an anti-
sense (A) or sense (Bl hybridization probe corresponding to the L-selectin ligand cDNA,
washed. exposed to emulsion for 6 weeks and developed. The morphology of the HEV is
shown with a dotted line surrounding the venule.
Figure 8. A model of the structure of the -50 kD Selectin ligand. illustrated is one
possible model for the structure of the ~ 50 kD L-selectin ligand on the luminal surface of the
peripheral lymph node HEV. The extended brush—like regions correspond to O-linked regions
I and II in a highly O-glycosylated state. The less-extended regions correspond to the N-
terminal and central serine/threonine poor domains. in this model, membrane attachment is
accomplished by oligomerization of the C-terminal amphipathic helical regions and insertion
of these regions into the membranes so that the polar regions interact with each other to
form an oligomer and the apolar faces of the helices interact with the lipid bilayer. As
described in the text, a number of other models are also equally likely.
DETAILED DESCRIPTION OF THE INVENTION
l. DEFlNlTlONS
The term "selectin ligand" and its grammatical variants, are used to refer to a
polypeptide having a qualitative biological property in common with a naturally occurring
ligand of a selectin molecule.
‘Biological property" in this context means an in viva effector or antigenic function or
activity that is directly or indirectly performed by a naturally occurring ligand of a selectin
molecule, or by any subsequence thereof. Effector functions include receptor binding, any
enzyme activity or enzyme modulatory activity, any carrier binding activity, any hormonal
activity, any activity in promoting or inhibiting adhesion of cells to extracellular matrix or cell
surface molecules, or any structural role. The antigenic functions essentially mean the
possession of an epitope or antigenic site that is capable of cross-reacting with antibodies
raised against a naturally occurring ligand of a selectin molecule.
‘Biologically active" selectin ligands share an effector function of a naturally occurring
ligand of a selectin molecule, which may, but need not, in addition possess an antigenic
function.
The selectin ligand as defined for the purpose of the present invention, preferably
comprises a sequence having the qualitative ability to bind a selectin, and having a highly O-
linked mucin-type, rod-like structure allowing for the presentation of its carbohydrates to the
lectin domain of a selectin.
In a further preferred embodiment, the selectin ligand comprises an amino acid
sequence encoded by a nucleotide sequence able to hybridize (under low stringency
conditions) to the complement of a nucleotide sequence encoding the protein having the
amino acid sequence shown in Figure 4.
The amino acid sequence of the protein core of the selectin ligand is preferably greater
than about 40% homologous, more preferably greater than about 60% homologous, still more
preferably greater than about 70% homologous, even more preferably greater than about
80%, and most preferably at least about 90% homologous with the amino acid sequence
shown in Figure 4.
"Homologous" is defined as the percentage of residues in the candidate amino acid
sequence that are identical with the residues in the amino acid sequence shown in Figure 4
after aligning the sequences and introducing gaps, if necessary, to achieve the maximum
percent homology.
The term "selectin ligand" specifically encompasses amino acid and glycosylation
variants of native selectin ligands, as well as their derivatives, such as those obtained by
covalent modifications, provided that they qualitatively retain a biological property possessed
by a naturally occurring ligand of a selectin molecule, and preferably the qualitative ability to
bind their receptors.
The term specifically encompasses glycoproteins comprising an amino acid sequence
having a biological property in common with a naturally occurring ligand of a selectin fused
to a stable plasma protein.
“Stable plasma proteins“ are proteins typically having about 30 to about 2000
residues, which exhibit in their native environment an extended half-life in the circulation, i.e.
-1].
a half-life greater than about 20 hours. Examples of suitable stable plasma proteins are
immunoglobulins, albumin, lipoproteins, apolipoproteins and transferrin. The amino acid
sequence having a qualitative biological property in common with a naturally occurring
selectin ligand is generally fused C-terminally to a stable plasma protein sequence, e.g.
immunoglobulin constant domain sequence.
The term "immunoglobulin" generally refers to polypeptides comprising a light or heavy
chain usually both disulfide bonded in the native "Y" configuration, although other linkage
between them, including tetramers or aggregates thereof, is within the scope hereof.
Ligand binding protein-stable plasma protein chimeras, and
known.
references cited therein.
specifically L-selectin-immunoglobulin chimeras are, for example, disclosed in W0 91/08298
published 13 June 1991. The immunoglobulin moiety in the chimera of the present invention
may be obtained from |gG,, lgG,, lgG3, or lgG4 subtypes, lgA, lgE, |gD or lgM, but preferably
lgG, or lgG3. T
The terms "nucleic acid molecule encoding", "DNA sequence encoding", and ‘DNA
encoding" refer to the order or sequence of deoxyribonucleotides along a strand of
deoxyribonucleic acid. The order of these deoxyribonucleotides determines the order of
amino acids along the polypeptide chain. The DNA sequence thus codes for the amino acid
sequence.
The term "isolated" when used in relation to a nucleic acid or a protein refers to a
nucleic acid or protein that is identified and separated from at least one containment nucleic
acid or protein with which it is ordinarily associated in its natural source. Isolated nucleic acid
or protein is such present in a form or setting that is different from that in which it is found
in nature. However, isolated nucleic acid encoding a selectin ligand includes such nucleic
acid in cells ordinarily expressing selectin ligands where the nucleic acid is in a chromosomal
location different from that of natural cells, or is otherwise flanked by a different DNA
sequence than that found in nature.
‘Low stringency conditions“ are overnight incubation at 37°C in a solution comprising:
% formamide, 5xSSC (150 mM NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate
(pH 7.6), 5 x Denhardt’s solution, 10% dextrane sulfate, and 20 pg/ml denatured, sheared
salmon sperm DNA, followed by washing the filters in ‘lx SSC at about 50°C.
Nucleic acid is "operably linked" when it is placed into a functional relationship with
another nucleic acid sequence. For example, DNA for a presequence or secretory leader is
operably linked to a DNA encoding a polypeptide if it is expressed as a preprotein that
participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to
a coding sequence if it affects the transcription of the sequence; or a ribosome binding site
is operably linked to a coding sequence if it is positioned so as to facilitate translation.
Generally, "operably linked" means that the DNA sequences being linked are contiguous and,
in the case of a secretory leader, contiguous and in reading phase. However, enhancers do
not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites.
If such sites do not exist, then synthetic oligonucleotide adaptors or linkers are used in accord
with conventional practice.
The terms "replicable expression vehicle" and “expression vehicle" refer to a piece of
DNA, usually double-stranded, which may have inserted into it a piece of foreign DNA.
Foreign DNA is defined as heterologous DNA, which is DNA not naturally found in the host
cell. The vehicle is used to transport the foreign or heterologous DNA into a suitable host
cell. Once in the host cell, the vehicle can replicate independently of the host chromosomal
DNA, and several copies of the vehicle and its inserted (foreign) DNA may be generated. In
addition, the vehicle contains the necessary elements that permit translating the foreign DNA
into a polypeptide. Many molecules of the polypeptide encoded by the foreign DNA can thus
be rapidly synthesized.
In the context of the present invention the expressions "cell", "cell line", and "cell
culture" are used interchangeably, and all such designations include progeny. It is also
understood that all progeny may not be precisely identical in DNA content, due to deliberate
or inadvertent mutations. Mutant progeny that have the same function or biological property
as screened for in the originally transformed cell are included.
The terms "transformed host cell" and "transformed" refer to the introduction of DNA
into a cell. The cell is termed a “host cell", and it may be a prokaryotic or a eukaryotic cell.
Typical prokaryotic host cells include various strains of _E_. Q. Typical eukaryotic host cells
are mammalian, such as Chinese hamster ovary cells or human embryonic kidney 293 cells.
The introduced DNA is usually in the form of a vector containing an inserted piece of DNA.
The introduced DNA sequence may be from the same species as the host cell or a different
species from the host cell, or it may be a hybrid DNA sequence, containing some foreign and
some homologous DNA.
"Ligation" refers to a process of forming phosphodiester bonds between two nucleic
acid fragments. To ligate the DNA fragments together, their ends must be compatible. In
some cases, the ends will be directly compatible after endonuclease digestion. However, it
may be necessary to first convert the staggered ends commonly produced after endonuclease
digestion to blunt ends to make them compatible for ligation. To blunt ends, the DNA is
treated in a suitable buffer for at least 15 minutes at 15°C with about 10 units of the Klenow
fragment of DNA polymerase I or T4 DNA polymerase in the presence of the four
deoxyribonucleotide triphosphates. The DNA is then purified by phenol-chloroform extraction
and ethanol precipitation. The DNA fragments that are to be ligated together are put in
solution in about equimolar amounts. The solution will also contain ATP, ligase buffer, and
a ligase such as T4 DNA ligase at about 10 units per 0.5 pg of DNA. If the DNA is to be
ligated into a vector, the vector is first linearized by digestion with the appropriate restriction
endonucleaselsl. The linearized fragment is then treated with bacterial alkaline phosphatase,
or calf intestinal phosphatase to prevent self-ligation during the ligation step.
The terms "amino acid‘ and "amino acids“ refer to all naturally occurring L-a-amino
acids. This definition is meant to include norleucine, ornithine, and homocysteine. The amino
acids are identified by either the single-letter or three-letter designations:
Asp D aspartic acid Ile I isoleucine
Thr T threonine Leu L leucine
Ser 5 eerine Ty: Y tyrosine
Glu E glutamic acid Phe F phenylalanine
Pro P proline His H histidine
Gly G glycine Lys K lysine
Ala A alanine Arg R arginine
cye C cysteine Trp W tryptophan
Val V valine Gln Q glutamine
Met M methionine Asn N asparagine
These amino acids may be classified according to the chemical composition and
properties of their side chains. They are broadly classified into two groups, charged and
uncharged. Each of these groups is divided into subgroups to classify the amino acids more
accurately:
l. Charged £11315; L:id_s
A_i.:i<fl Residues: aspartic acid, glutamic acid
Basic Residues: lysine, arginine, histidine
ll. Unchargeg Amino Acids
H dro hilic : serine, threonine, asparagine, glutamine
ilipbitjg : glycine, alanine, valine, leucine, isoleucine
: cysteine, methionine, proline
A_r_cmati_c : phenylalanine, ‘tyrosine, tryptophan
The terms "alteration", "amino acid sequence alteration", "variant" and "amino acid
sequence variant‘ refer to molecules with some differences in their amino acid sequences as
compared to the native sequence of a selectin, e.g. an L-selectin ligand. Ordinarily, the
variants will possess at least 70% homology with a native selectin ligand, and preferably,
they will be at least about 80%, more preferably at least about 90% homologous with a
native selectin ligand. The amino acid sequence variants falling within this invention possess
substitutions, deletions, and/or insertions at certain within the amino acid sequence of a
native selectin ligand. Substitutional variants are those that have at least one amino acid
residue in a native sequence removed and a different amino acid inserted in its place at the
same position. The substitutions may be single, where only one amino acid in the molecule
has been substituted, or they may be multiple, where two or more amino acids have been
substituted in the same molecule.
Substantial changes in the properties of the ligand may be obtained by substituting an
amino acid with a side chain that is significantly different in charge and/or structure from that
of the native amino acid. This type of substitution would be expected to affect the structure
of the polypeptide backbone and/or the charge or hydrophobicity of the molecule in the area
of the substitution.
Moderate changes in the ligand properties would be expected by substituting an amino
acid with a side chain that is similar in charge and/or structure to that of the native molecule.
This type of substitution, referred to as a conservative substitution, would not be expected
to substantially alter either the structure of the polypeptide backbone or the charge or
hydrophobicity of the molecule in the area of the substitution.
lnsertional variants are those with one or more amino acids inserted immediately
adjacent to an amino acid at a particular position in a native selectin ligand sequence.
Immediately adjacent to an amino acid means connected to either the a—carboxy or a-amino
functional group of the amino acid. The insertion may be one or more amino acids.
Ordinarily, the insertion will consist of one or two conservative amino acids. Amino acids
similar in charge and/or structure to the amino acids adjacent to the site of insertion are
defined as conservative. Alternatively, this invention includes insertion of an amino acid with
a charge and/or structure that is substantially different from the amino acids adjacent to the
site of insertion.
Deletional variants are those with one or more amino acids in the native selectin ligand
amino acid sequence removed. Ordinarily, deletional variants will have one or two amino
acids deleted in a particular region of the molecule.
An essential role of the protein core of the present selectin ligands is to present the
specific carbohydrate structure recognized by a selectin receptor to the respective receptor.
Accordingly, any alteration within the two highly O-glycosylated, serine- and threonine-
rich regions (amino acids 42-63 and amino acids 93-122 in Figure 4) of the L-selectin ligand
amino acid sequence is expected to have more significant effect on the lymphocyte~high
endothelial venule interaction than changes in other regions of the protein. As it will be
shown hereinbelow, the highly O-glycosylated regions are essential to provide a rigid,
inflexible "bottle brush" structure that allows for the large number of 0-linked carbohydrate
ligands attached to the serine and threonine residues to be appropriately presented to the
leukocyte surface-localized L-selectin lectin domains, thereby mediating the carbohydrate-
dependent adhesive interaction. Alterations within these regions are expected to result in
molecules the receptor binding activities of which will be significantly different from that of
the corresponding native ligand.
The glycoprotein ligands of the present invention comprise fucose, sialic acid and an
anionic component, preferably sulfate esters as Oi-linked carbohydrate components, and it is
believed that fucose, like sialic acid, and sulfate are required for full ligand activity.
Examples of specific carbohydrate components of the glycoprotein ligands of the
invention can be expressed as follows:
NeuNAca2-3Gal[:‘1-4lFuca1-3)GlcNAc
NeuNAcA2-3Gal/?1-4GlcNAcB1-3GalB1-4(FucA1-4(FucA1-3)GlcNAc.
"Northern blot analysis" is a method used to identify RNA sequences that hybridize to
a known probe such as an oligonucleotides, DNA fragment, cDNA or fragment thereof, or
RNA fragment. The probe is labeled with a radioisotope such as ”P, or by biotinylation, or
with an enzyme. The RNA to be analyzed is usually electrophoretically separated on an
agarose or polyacrylamide gel, transferred to nitrocellulose, nylon, or other suitable
membrane, and hybridized with the probe, using standard techniques well known in the art
such as those described in sections 7.39-7.52 of Sambrook et a/., Molecular Cloning: A
Laboratgry Manual, New York: Cold Spring Harbor Laboratory Press, 1989.
"O|igonucleotides" are short-length, single- or double—stranded polydeoxynucleotides
that are chemically synthesized by known methods [such as phosphotriester, phosphite, or
phosphoramidite chemistry, using solid phase techniques such as those described in EP
266,032, published 4 May 1988, or via deoxynucleoside H-p -usphanate intermediates as
described by Froehler er a/., _l\l_tigl._i0t_c_i¢_jfie_s. 13, 5399 (1986)). They are then purified on
polyacrylamide gels.
The technique of “polymerase chain reaction" or "PCR", as used herein, generally
refers to a procedure wherein minute amounts of a specific piece of nucleic acid, RNA and/or
DNA, are amplified as described in U.S. Patent No. 4,683,195, issued 28 July 1987 and in
Current Protocols in Molecular BlOl0ClV. Ausubel et al. eds., Greene Publishing Associates and
Vlfiley-lnterscience 1991, Volume 2, Chapter 15.
"Transformation" means introducing DNA into an organism so that the DNA is
replicable, either as an extrachromosomal element or by chromosomal integration.
"Transfection" refers to the taking up of an expression vector by a host cell whether
or not any coding sequences are in fact expressed.
The terms "treatment", "treating" and grammatical variants thereof, are used in the
broadest sense and include prevention and amelioration of certain undesired symptoms or
conditions.
“Gas phase microsequencing" was accomplished based upon the following procedures.
The purified protein was either sequenced directly by automated Edman degradation with a
model 470A Applied Biosystems gas phase sequencer equipped with a 120A PTH amino acid
analyzer or sequenced after digestion with various chemicals or enzymes. PTH amino acids
were integrated using a ChromPerfect data system (Justice Innovations, Palo Alto, CA).
Sequence interpretation was performed on a VAX 11/785 Digital Equipment Corporation
computer as described by Henzel er a/., J. Chromatograghy Q93, 41 (1987). In some cases,
aliquots of the HPLC fractions are electrophoresed on 5—20% SDS polyacrylamide gels,
electrotransferred to a PVDF membrane (ProBlott, ABl, Foster City, CA) and stained with
Coomassie Brilliant Blue [Matsudaira, P.J., Big). Chem. _2_6_2_, 10035 (1987ll. The specific
protein was excised from the blot for N-terminal sequencing. To determine internal protein
sequences, HPLC fractions were dried under vacuum lSpeedVac), resuspended in appropriate
buffers, and digested with cyanogen bromide, the lysine-specific enzyme Lys-C (Wake
Chemicals, Richmond, VA) or Asp—N lBoehringer Mannheim, Indianapolis, Ind.). After
digestion, the resultant peptides were sequenced as a mixture or were resolved by HPLC on
a C4 column developed with a propanol gradient in 0.1 % TFA before sequencing as described
above.
The term "monoclonal antibody" as used herein refers to an antibody obtained from
a population of substantially homogeneous antibodies, i.e., the individual antibodies
- comprising the population are identical except for possible naturally occurring mutations that
may be present in minor amounts. Thus, the modifier “monoclonal” indicates the character
of the antibody as not being a mixture of discrete antibodies.
The monoclonal antibodies included within the scope of the invention include hybrid
and recombinant antibodies produced by splicing a variable (including hypervariable) domain
of an anti-selectin ligand antibody with a constant domain le.g. "humanized" antibodies), only
one of which is directed against a selectin ligand, or a light chain with a heavy chain, or a
chain from one species with a chain from another species, or fusions with heterologous
proteins, regardless of species of origin or immunoglobulin class or subclass designation, as
well as antibody fragments (e.g., Fab, F(ab’l2, and Fv). Cabilly, e_t _a_|., U.S. Pat. No.
4,816,567; Mage & Lamoyi, in Monoclonal Antibody Production Technigues and
Aggligations, pp.79-97 (Marcel Dekker, lnc., New York, 1987).
Thus, the modifier "monoclonal" indicates the character of the antibody as being
obtained from such a substantially homogeneous population of antibodies, and is not to be
construed as requiring production of the antibody by any particular method.
The DNA encoding a selectin ligand may be obtained from any cDNA library prepared
from tissue believed to possess mRNA for the selectin ligand and to express it at a detectable
level. An L-selectin ligand gene thus may be obtained from a cDNA library prepared from
(mesenteric or peripheral) lymph nodes. Genes encoding the other selectin ligands can be
prepared from other cDNA libraries in an analogous manner.
Libraries are screened with probes designed to identify the gene of interest or the
protein encoded by it. For cDNA expression libraries, suitable probes usually include mono-
and polyclonal antibodies that recognize and specifically bind to the desired protein;
oligonucleotides of about 20-80 bases in length that encode known or suspected portions of
the selectin ligand cDNA from the same or different species; and/or complementary or
homologous cDNAs or their fragments that encode the same or similar gene.
An alternative means to isolate the gene encoding a selectin ligand, e.g. an L-selectin
ligand, is to use polymerase chain reaction lPCR) methodology as described in section 14 of
Sambrook et a/., Sugra or in Chapter 15 of Current Protocgls in Molecular Biglogy, Sugra.
Another alternative is to chemically synthesize the gene encoding the desired selectin
ligand using one of the methods described in Engels er a/., Agnew. Chem. Int. Ed. Engl. _2_&,
716 (1989). These methods include triester, phosphite, phosphoramidite and H-Phosphonate
methods, PCR and other autoprimer methods, and oligonucleotide syntheses on solid
supports. These methods may be used if the entire nucleic acid sequence of the gene is
known, or the sequence of the nucleic acid complementary to the coding strand is available,
or, alternatively, if the target amino acid sequence is known, one may infer potential nucleic
acid sequences, using known and preferred coding residues for each amino acid residue.
A preferred method for practicing this invention is to use carefully selected
oligonucleotide sequences to screen cDNA libraries from various tissues. preferably
mammalian lymph node high endothelial venules (L-selectin ligand), or myeloid cells (E-selectin
and P—selectin ligands). Among the preferred mammals are humans and members of the
following orders: bovine, ovine, equine, murine, and rodentia.
The oligonucleotide sequences selected as probes should be of sufficient length and
sufficiently unambiguous that false positives are minimized. The actual nucleotide
sequencels) is/are usually based on conserved or highly homologous nucleotide sequences
or regions of a selectin ligand, e.g. L—selectin ligand.
The DNA shown in Figure 4 may be used to isolate DNA encoding other selectin
ligands for to isolate DNA encoding L-selectin ligand from another animal species via
hybridization employing the methods discussed above. The preferred animals are mammals,
particularly human, bovine, ovine, equine, feline, canine and rodentia, and more specifically
human, bovine, rats, and rabbits.
B. Construction Q Amino Acid Seggence Variants
The amino acid sequence variants of the selectin ligands of this invention are preferably
constructed by mutating the DNA sequence that encodes the protein core of a wild-type
selectin, e.g. L-selectin ligand. Generally, particular regions or sites of the DNA will be
targeted for mutagenesis, and thus the general methodology employed to accomplish this is
termed site-directed mutagenesis. The mutations are made using DNA modifying enzymes
such as restriction endonucleases (which cleave DNA at particular locations), nucleases
(which degrade DNA) and/or polymerases iwhich synthesize DNA).
generate deletions, as described in section 15.3 of Sambrook et al., &gr_a_. To use this
method, it is preferable that the foreign DNA be inserted into a plasmid vector. A restriction
map of both the foreign (inserted) DNA and the vector DNA must be available, or the
sequence of the foreign DNA and the vector DNA must be known. The foreign DNA must
have unique restriction sites that are not present in the vector. Deletions are then made in
the foreign DNA by digesting it between these unique restriction sites, using the appropriate
restriction endonucleases under conditions suggested by the manufacturer of the enzymes.
lf the restriction enzymes used create blunt ends or compatible ends, the ends can be directly
ligated together using a ligase such as bacteriophage T4 DNA ligase and incubating the
mixture at 16°C for 1-4 hours in the presence of ATP and ligase buffer as described in
section 1.68 of Sambrook et al., _S_gma. If the ends are not compatible, they must first be
made blunt by using the Klenow fragment of DNA polymerase l or bacteriophage T4 DNA
polymerase, both of which require the four deoxyribonucleotide triphosphates to fill-in the
overhanging single-stranded ends of the digested DNA. Alternatively, the ends may be
blunted using a nuclease such as nuclease S1 or mung-bean nuclease, both of which function
by cutting back the overhanging single strands of DNA. The DNA is then religated using a
ligase. The resulting molecule is a deletion variant.
A similar strategy may be used to construct insertion variants, as described in section
.3 of Sambrook et al., Supra. After digestion of the foreign DNA at the unique restriction
site(s), an oligonucleotide is ligated into the site where the foreign DNA has been cut. The
oligonucleotide is designed to code for the desired amino acids to be inserted and additionally
has 5’ and 3' ends that are compatible with the ends of the foreign DNA that have been
digested, such that direct ligation is possible.
. -Mediated Mutagenesis
Oligonucleotide-directed mutagenesis is the preferred method for preparing the
substitution variants of this invention. it may also be used to conveniently prepare the
deletion and insertion variants of this invention. This technique is well known in the art as
described by Adelman et al. (ml_A. _Z:183 H9831).
The DNA template molecule is the single-stranded form of the vector with its wild-type
cDNA t-PA insert. The single-stranded template can only be generated by those vectors that
are either derived from bacteriophage M13 vectors (the commercially available M13mp18 and
M13mp19 vectors are suitable), or those vectors that contain a single-stranded phage origin
of replication as described by Veira et al. (Meth. Enzymol., J_5_,'1:3 (1987)). Thus, the cDNA
t-PA that is to be mutated must be inserted into one of these vectors in order to ‘generate
single-stranded template. Production of the single-stranded template is described in sections
4.21-4.41 of Sambrook et al., flgg.
To mutagenize the native selectin ligand sequence, the oligonucleotide is annealed to
the single-stranded DNA template molecule under suitable hybridization conditions. A DNA
polymerizing enzyme, usually the Klenow fragment of 5. gglj DNA polymerase I, is then
added. This enzyme uses the oligonucleotide as a primer to complete the synthesis of the
mutation—bearing strand of DNA. Thus, a heteroduplex molecule is formed such that one
strand of DNA encodes the native selectin ligand inserted in the vector, and the second
strand of DNA encodes the mutated form of the selectin ligand inserted into the same vector.
This heteroduplex molecule is then transformed into a suitable host cell, usually a prokaryote
such as g. go_li JM101. After growing the cells, they are plated on to agarose plates and
screened using the oligonucleotide primer radiolabeled with 32-P to identify the colonies that
contain the selectin ligand mutated in its protein core. These colonies are selected, and the
DNA is sequenced to confirm the presence of mutations in the protein core of the molecule.
Mutants with more than one amino acid substituted may be generated in one of several
ways If the amino acids are located close together in the polypeptide chain, they may be
mutated simultaneously using one oligonucleotide that codes for all of the desired amino acid
substitutions. If, however, the amino acids are located some distance from each other
(separated by more than ten amino acids, for example) it is more difficult to generate a single
oligonucleotide that encodes all of the desired changes. lnstead, one of two alternative
methods may be employed. In the first method, a separate oligonucleotide is generated for
each amino acid to be substituted. The oligonucleotides are then annealed to the single-
stranded template DNA simultaneously, and the second strand of DNA that is synthesized
from the template will encode all of the desired amino acid substitutions. The alternative
method involves two or more rounds of mutagenesis to produce the desired mutant. The first
round is as described for the single mutants: DNA encoding the protein core of a native
selectin ligand is used for the template, an oligonucleotide encoding the first desired amino
acid substitutionlsl is annealed to this template, and the heteroduplex DNA molecule is then
generated. The second round of mutagenesis utilizes the mutated DNA produced in the first
round of mutagenesis as the template. Thus, this template already contains one or more
mutations. The oligonucleotide encoding the additional desired amino acid substitutionlsl is
then annealed to this template, and the resulting strand of DNA now encodes mutations from
both the first and second rounds of mutagenesis. This resultant DNA can be used as a
template in a third round of mutagenesis, and so on.
; PQR Mutagenesis
PCR mutagenesis is also suitable for making amino acid variants of the selectin ligands
of the present invention. While the following discussion refers to DNA, it is understood that
the technique also find application with RNA. The PCR technique generally refers to the
following procedure. When small amounts of template DNA are used as starting material in
a PCR, primers that differ slightly in sequence from the corresponding region in a template
DNA can be used to generate relatively large quantities of a specific DNA fragment that
differs from the template sequence only at the positions where the primers differ from the
template. For introduction of a mutation into a plasmid DNA, one of the primers is designed
to overlap the position of the mutation and to contain the mutation; the sequence of the other
primer must be identical to a stretch of sequence of the opposite strand of the plasmid, but
this sequence can be located anywhere along the plasmid DNA. It is preferred, however, that
the sequence of the second primer is located within 200 nucleotides from that of the first,
such that in the end the entire amplified region of DNA bounded by the primers can be easily
sequenced. PCR amplification using a primer pair like the one just described results in a
population of DNA fragments that differ at the position of the mutation specified by the
primer, and possibly at other positions, as template copying is somewhat error-prone.
If the ratio of template to product material is extremely low, the vast majority of
product DNA fragments incorporate the desired mutationlsl. This product material is used
to replace the corresponding region in the plasmid that served as PCR template using
-21.
standard DNA technology. Mutations at separate positions can be introduced simultaneously
by either using a mutant second primer or performing a second PCR with different mutant
primers and ligating the two resulting PCFI fragments simultaneously to the vector fragment
in a three (or more)-part ligation.
present invention is inserted into a replicable vector for further cloning or expression. Many
vectors are available, and selection of the appropriate vector will depend on 1) whether it is
to be used for DNA amplification (cloning) or for expression, 2) the size of the DNA to be
inserted into the vector, and 3) the host cell to be transformed with the vector. Each vector
contains various components depending on its function and the host cell with which it is
compatible. The vector components generally include, but are not limited to, one or more of
the following: a signal sequence, an origin of replication, one or more marker genes, an
enhancer element, a promoter and a transcription terminator sequence. Specific vectors will
be discussed hereinbelow in conjunction with the host cells with which they are
compatible. '
Suitable vectors are prepared using standard recombinant DNA procedures. Isolated
plasmids and DNA fragments are cleaved, tailored, and ligated together in a specific order to
generate the desired vectors.
The DNA is cleaved using the appropriate restriction enzyme or enzymes in a suitable
buffer. ln general, about 0.2-1 /J9 of plasmid or DNA fragments is used with about 1-2 units
of the appropriate restriction enzyme in about 20 pl of buffer solution. (Appropriate buffers,
DNA concentrations, and incubation times and temperatures are specified by the
manufacturers of the restriction enzymes.) Generally, incubation times of about one or two
hours at 37°C are adequate, although several enzymes require higher temperatures. After
incubation, the enzymes and other contaminants are removed by extraction of the digestion
solution with a mixture of phenol and chloroform, and the DNA is recovered from the aqueous
fraction by precipitation with ethanol.
To ligate the DNA fragments together to form a functional vector, the ends of the DNA
fragments must be compatible with each other. In some cases the ends will be directly
compatible after endonuclease digestion. However, it may be necessary to first convert the
sticky ends, commonly produced by endonuclease digestion, to blunt ends to make them
compatible for ligation. To blunt the ends, the DNA is treated in a suitable buffer for at least
minutes at 15°C with 10 units of the Klenow fragment of DNA Polymerase l lKlenow) in
the presence of the four deoxynucleotide triphosphates. It is then purified by phenol-
chloroform extraction and ethanol precipitation.
The cleaved DNA fragments may be size-separated and selected using DNA gel
electrophoresis. The DNA may be electrophoresed through either an agarose or a
polyacrylamide matrix. The selection of the matrix will depend on the size of the DNA
fragments to be separated. After electrophoresis, the DNA is extracted from the matrix by
electroelution, or, if low-melting agarose has been used as the matrix, by melting the agarose
and extracting the DNA from it, as described in sections 6.30-6.33 of Sambrook et al., flpia,
The DNA fragments that are to be ligated together (previously digested with the
appropriate restriction enzymes such that the ends of each fragment to be ligated are
compatible) are present in solution in about equimolar amounts. The solution will also contain
ATP, ligase buffer and a ligase such as T4 DNA ligase at about 10 units per 0.5 pg of DNA.
If the DNA fragment is to be ligated into a vector, the vector is first linearized by cutting with
the appropriate restriction endonuclease(s) and then phosphatased with either bacterial
alkaline phosphatase or calf intestinal alkaline phosphatase. This prevents self-ligation of the
vector during the ligation step.
. Eukarvotic Multicellular Organisms
Multicellular organisms are preferred as hosts to practice this invention. While both
invertebrate and vertebrate cell cultures are acceptable, vertebrate cell cultures, particularly
mammalian cultures, are preferable. Examples of suitable cell lines include monkey kidney
CVI line transformed by SV40 (COS—7, ATCC CRL 1651); human embryonic kidney line 2935
(Graham et al., J. Gen. Virol., £59 [1977]l; baby hamster kidney cells (BHK, ATCC CCL
); Chinese hamster ovary cells (Urlab and Chasin, , ]_Z:42l6
(19801); mouse sertoli cells (TM4, Mather, , £35243 (19801); monkey kidney
cells (CVI-76, ATCC CCL 70); African green monkey kidney cells (VERO-76, ATCC CRL-
); human cervical carcinoma cells lHELA, ATCC CCL 2); canine kidney cells (MDCK,
ATCC CCL 34); buffalo rat liver cells lBRL 3A, ATCC CRL 1442): human lung cells (W138,
ATCC CCL 75); human liver cells (Hep G2, HB 8065); mouse mammary tumor cells (MMT
060562, ATCC CCL 51); rat hepatoma cells lHTC, ML54, Baumann at a|,, _J_ can 3301” 35:1
M9801); and TR) cells (Mather et aI., Annals N.Y. Acad. Sci., _:_3_8_3_:44 [1982]). Expre;-i-on
vectors for these cells ordinarily include (if necessary) DNA sequences for an origin of
replication, a promoter located in front of the gene to be expressed, a ribosome binding site,
an RNA splice site, a polyadenylation site, and a transcription terminator site.
Alternatively, promoters that are naturally associated with the foreign gene
lhomologous promoters) may be used provided that they are compatible with the host cell
line selected for transformation.
An origin of replication may be obtained from an exogenous source, such as SV40 or
other virus (_e.g.. Polyoma, Adeno, VSV, BPV) and inserted into the cloning vector.
Alternatively, the origin of replication may be provided by the host cell chromosomal
replication mechanism. If the vector containing the foreign gene is integrated into the host
cell chromosome, the latter is often sufficient.
Satisfactory amounts of selectin ligand can be produced by transformed cell cultures.
‘However, the use of a secondary DNA coding sequence can enhance production levels. The
secondary coding sequence typically comprises the enzyme dihydrofolate reductase (DHFR).
The wild-type form of DHFR is normally inhibited by the chemical methotrexate (MTX). The
level of DHFR expression in a cell will vary depending on the amount of MTX added to the
cultured host cells. An additional feature of DHFR that makes it particularly useful as a
secondary sequence is that it can be used as a selection marker to identify transformed cells.
Two forms of DHFR are available for use as secondary sequences, wild-type DHFR and
MTX-resistant DHFR. The type of DHFR used in a particular host cell depends on whether
the host cell is DHFR deficient (such that it either produces very low levels of DHFR
endogenously, or it does not produce functional DHFR at all). DHFR-deficient cell lines such
as the CH0 cell line described by Urlaub and Chasin (Proc. Natl. Acad. Sci. (USA) ]_7:42l6
ll 980)) are transformed with wild-type DHFR coding sequences. After transformation, these
DHFR-deficient cell lines express functional DHFR and are capable of growing in a culture
medium lacking the nutrients hypoxanthine, glycine and thymidine. Nontransformed cells will
not survive in this medium.
The MTX-resistant form of DHFR can be used as a means of selecting for transformed
host cells in those host cells that endogenously produce normal amounts of functional DHFR
that is MTX sensitive. The CHO-K1 cell line (ATCC number CL 61) possesses these
characteristics, and is thus a useful cell line for this purpose. The addition of MTX to the cell
culture medium will permit only those cells transformed with the DNA encoding the MTX-
resistant DHFR to grow. The nontransformed cells will be unable to survive in this medium.
The mammalian host cells used to produce the variants of this invention may be
cultured in a variety of media. Commercially available media such as Ham's F10 (Sigma),
Minimal Essential Medium ([MEM], Sigma), RPM)-1640 (Sigma). and Dulbecco's Modified
Eagle's Medium ([DMEM], Sigma) are suitable for culturing the host cells. Any of these media
may be supplemented as necessary with hormones and/or other growth factors (such as
insulin, transferrin, or epidermal growth factor), salts (such as sodium chloride, calcium,
magnesium, and phosphate), buffers (such as HEPES), nucleosides (such as adenosine and
thymidine), antibiotics (such as Gentamycin). trace elements (defined as inorganic compounds
usually present at final concentrations in the micromolar range), and glucose or an equivalent
energy source. Any other necessary supplements may also be included at appropriate
concentrations that would be known to those skilled in the art.
. Eukaggotic Microbes
In addition to multicellular eukaryotes, eukaryotic microbes such as filamentous fungi
reesia [EP 244,234]; Neurosgora crassa [Case et al., Proc. Natl. Acad. Sci. USA, E5259
(1979)); Schwanniomyces such as Schwanniomyces ocgidentalis [EP 394,538 published 31
October 1990]; and filamentous fungi such as, e.g., Neurospora, Penicillium, Tolvnocladium
[W0 91/00357 published 10 January 1991], and Asgergillus hosts such as A; nidulans
[Ballance et al., Biochem. Biophys. Res. Commun., _1__1_2:284 (1983): Tilburn et al., Gene,
.25.
_6_:205 (1983); Yelton et al., Proc. Natl. Acad. Sci. USA, _8_1_:147O (1984l] and A_. gjge_r
[Kelly and Hynes, , 5:475 11985)}.
Suitable promoting sequences in yeast vectors include the promoters for 3-
phosphoglycerate kinase lHitzeman et al., J. Biol. Chem., _2_fi:2073 [1980]l or other
glycolytic enzymes (Hess et al., J. Adv. Enzyme Reg., _7_:149 I1 9681; Holland et al.,
. J_Z:4900l1978]l, such as enolase, glyceraldehydephosphate dehydrogenase,
hexokinase, pyruvate decarboxylase, phosphofructokinase. glucosephosphate isomerase,
3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose
isomerase, and glucokinase. In the construction of suitable expression plasmids, the
termination sequences associated with these genes are also ligated into the expression vector
3’ of the sequence desired to be expressed to provide polyadenylation of the mRNA and
termination. Other promoters that have the additional advantage of transcription controlled
by growth conditions are the promoter region for alcohol dehydrogenase 2, isocytochrome
C.. acid phosphatase. degradative enzymes associated with nitrogen metabolism, and the
aforementioned gIyceraldehydephosphate dehydrogenase, and enzymes responsible for
maltose and galactose utilization. Any plasmid vector containing yeast-compatible promoter,
origin of replication and termination sequences is suitable.
Prokaryotes may also be used as hosts for expression of DNA sequences. The E. _c_o1i
strains listed above, bacilli such as Bacillus subtilis, other enterobacteriaceae such as
Salmonella tyghimurium or Serratia marcesans, and various Pseugomonas species may all be
used as hosts.
Plasmid vectors containing replicon and control sequences that are derived from
species compatible with the host cell are used with these hosts. The vector usually has a
replication site, marker genes that provide phenotypic selection in transformed cells, one or
more promoters, and a polylinker region containing several restriction sites for insertion of
foreign DNA. Plasmids typically used for transformation of E. _c_ofi include pBR322, pUC18,
pUC19, pUC118, pUC119, and Bluescript M13, all of which are described in sections 1.12-
1.20 of Sambrook et al.. ggga. However, many other suitable vectors are available as well.
These vectors contain genes coding for ampicillin and/or tetracycline resistance which enables
cells transformed with these vectors to grow in the presence of these antibiotics.
,776), and the alkaline phosphatase systems. While these are the most commonly used
Many eukaryotic proteins normally secreted from the cell contain an endogenous signal
sequence as‘ part of the amino acid sequence. This sequence targets the protein for export
from the cell via the endoplasmic reticulum and Golgi apparatus. The signal sequence is
typically located at the amino terminus of the protein, and ranges in length from about 13 to
about 36 amino acids. Although the actual sequence varies among proteins, all known
eukaryotic signal sequences contain at least one positively charged residue and a highly
hydrophobic stretch of 10-15 amino acids (usually rich in the amino acids leucine, isoleucine,
alanine, valine and phenylalanine) near the center of the signal sequence. The signal
sequence is normally absent from the secreted form of the protein, as it is cleaved by a signal
peptidase located on the endoplasmic reticulum during translocation of the protein into the
endoplasmic reticulum. The protein with its signal sequence still attached is often referred
to as the 'pre-protein’ or the immature form of the protein.
However, not all secreted proteins contain an amino terminal signal sequence that is
cleaved. Some proteins, such as ovalbumin, contain a signal sequence that is located on an
internal region of the protein. This sequence is not normally cleaved during translocation.
Proteins normally found in the cytoplasm can be targeted for secretion by linking a
signal sequence to the protein. This is readily accomplished by ligating DNA encoding a
signal sequence to the 5’ end of the DNA encoding the protein and then expressing this
fusion protein in an appropriate host cell. The DNA encoding the signal sequence may be
obtained as a restriction fragment from any gene encoding a protein with a signal sequence.
Thus, prokaryotic, yeast, and eukaryotic‘ signal sequences may be used herein, depending on
the type of host cell utilized to practice the invention. The DNA encoding the signal sequence
portion of the gene is excised using appropriate restriction endonucleases and then ligated
to the DNA encoding the protein to be secreted.
Selection of a functional signal sequence requires that the signal sequence is
recognized by the host cell signal peptidase such that cleavage of that signal sequence and
secretion of the protein will occur. The DNA and amino acid sequence encoding the signal
sequence portion of several eukaryotic genes including, for example, human growth hormone,
proinsulin, and proalbumin are known (see Stryer, Biochemistry, W.H. Freeman and Company,
.27-
New York (19881. D. 769) and can be used as signal sequences in appropriate eukaryotic host
cells. Yeast signal sequences, as for example acid phosphatase lArima et al., Nuc. Acids
E. 1_1:1657 (19831). alpha-factor, alkaline phosphatase and invertase may be used to
direct secretion from yeast host cells. Prokaryotic signal sequences from genes encoding,
for example, LamB or OmpF (Wong et al., Gene _6_8_:193 19881), MalE, PhoA, or beta-
lactamase, as well as other genes, may be used to target proteins from prokaryotic cells into
the culture medium. 8
An alternative technique to provide a protein of interest with a signal sequence such
that it may be secreted is to chemically synthesize the DNA encoding the signal sequence.
In this method, both strands of an oligonucleotide encoding the selected signal sequence are
chemically synthesized and then annealed to each other to form a duplex. The double-
stranded oligonucleotide is then ligated to the 5' end of the DNA encoding the protein.
The construct containing the DNA encoding the protein with the signal sequence
ligated to it can then be ligated into a suitable expression vector. This expression vector is
transformed into an appropriate host cell and the protein of interest is expressed and
secreted.
E. Transformation Methggs
Cultures of mammalian host cells and other host cells that do not have rigid cell
membrane barriers are usually transformed using the calcium phosphate method as originally
described by Graham and Van der Eb (Virology, $546 (19781) and modified as described
in sections 16.32-16.37 of Sambrook et al. _®_q_r_a. However, other methods for introducing
DNA into cells such as Polybrene (Kawai and Nishizawa, Mol. Cell. Bigl., $1172 (19841).
protoplast fusion (Schaffner, Proc. Natl. Aged. Sci. USA, _Z1:2163 (19801), electroporation
(Neumann et al., EMBO J., 1:841 H9821), and direct microinjection into nuclei (Capecchi,
Qfl, _2_2:479 (1980)) may also be used.
F. Culturing The Host Cells
The mammalian host cells used to produce the selectin ligands of the present invention
epidermal growth factor), salts (such as sodium chloride, calcium, magnesium, and
phosphate), buffers (such as HEPES) nucleosides (such as adenosine and thymidine),
antibiotics (such as Gentamycin”), trace elements (inorganic compounds usually present at
final concentrations in the micromolar range), and glucose or an equivalent energy source.
Any other necessary supplements may also be included at appropriate concentrations that
would be known to those skilled in the art. The culture conditions, such as temperature, pH
and the like, are those previously used for the host cell selected for expression, and will be
apparent to the ordinarily skilled artisan.
Q gfilycgsylation Variants
Glycosylation of polypeptides is typically either N-linked or O-linked. N-linked refers
to the attachment of the carbohydrate moiety to the side-chain of an asparagine residue. The
tripeptide sequences, asparagine—X-serine and asparagine-X-threonine, wherein X is any amino
acid except proline, are recognition sequences for enzymatic attachment of the carbohydrate
moiety to the asparagine side chain. O-linked glycosylation refers to the attachment of one
of the sugars N-acetylgalactosamine, galactose, or xylose to a hydroxyamino acid, most
commonly serine or threonine, although 5-hydroxyproline or 5-hydroxylysine may also be
involved in O-linked glycosylation.
The selectin ligands of the present invention are characterized by the prevalence of O-
linked glycoslation sites. These may, for example, be modified by the addition of, or
substitution by, one or more serine or threonine residue to the amino acid sequence of the
ligand. For ease, changes are usually made at the DNA level, essentially using the techniques
discussed hereinabove with respect to the amino acid sequence variants.
Chemical or enzymatic coupling of glycosydes to the ligands of the present invention
may also be used to modify or increase the number or profile of carbohydrate substituents.
These procedures are advantageous in that they do not require production of the polypeptide
that is capable of O-linked (or N-linked) glycosylation. Depending on the coupling mode used,
the sugarls) may be attached to (a) arginine and histidine, (b) 'free carboxyl groups, (c) free
hydroxyl groups such as those of cysteine. ld) free sulfhydryl groups such as those of serine,
threonine, or hydroxyproline, (e) aromatic residues such as those of phenylalanine, tyrosine,
or tryptophan or (f) the amide group of glutamine. These methods are described in W0
87/05330 (published 11 September 1987), and in Aplin and Wriston, QRQ; (grit. Rev.
Biochem., pp. 259-306 (1981).
Carbohydrate moieties present on a selectin ligand may also be removed chemically or
enzymatically. Chemical deglycosylation requires exposure to trifluoromethanesulfonic acid
or an equivalent compound. This treatment results in the cleavage of most or all sugars,
except the linking sugar, while leaving the polypeptide intact. Chemical deglycosylation is
described by Hakimuddin et al., Arch. Biochem. Biophvs. 259, 52 (1987) and by Edge et a/.,
Anal. Biochem. E, 131 (1981). Carbohydrate moieties can be removed by a variety of
endo— and exoglycosidases as described by Thotakura er a/., Meth. Enzymol. fig, 3
(1987l. Glycosylation is suppressed by tunicamycin as described by Duskin er a/., J. Biol.
£h_e_r; _2.fl, 3105 (1982).
linkages.
Tunicamycin blocks the formation of protein-N-glycosydase
Glycosylation variants of the selectin ligands herein can also be produced by selecting
appropriate host cells. Yeast, for example, introduce glycosylation which varies significantly
from that of mammalian systems. Similarly, mammalian cells having a different species le.g.
hamster, murine, insect, porcine, bovine or ovinel or tissue le.g. lung, liver, lymphoid,
mesenchymal or epidermal) origin than the source of the selectin ligand, are routinely
screened for the ability to introduce variant glycosylation as characterized for example, by
elevated levels of mannose or variant ratios of mannose, fucose, sialic acid, and other sugars
essential for selectin binding.
ii, Qgvalgnt Modifications
Covalent modifications of a naturally occurring selectin ligand molecule or a sequence
having a biological property in common with such molecule, are included within the scope
herein. Such modifications are traditionally introduced by reacting targeted amino acid
residues of the selectin ligand protein with an organic derivatizing agent that is capable of
reacting with selected side-chains or terminal residues, or by harnessing mechanisms of post-
translational modifications that function in selected recombinant host cells. The resultant
covalent derivatives are useful in programs directed at identifying residues important for
biological activity, for immunoassays of the selectin ligands, or for the preparation of anti-
selectin ligand antibodies for immunoaffinity purification of the recombinant glycoprotein. For
example, complete inactivation of the biological activity of the protein after reaction with
ninhydrin would suggest that at least one arginyl or lysyl residue is critical for its activity,
whereafter the individual residues which were modified under the conditions selected are
identified by isolation of a peptide fragment containing the modified amino acid residue. Such
modifications are within the ordinary skill in the art and are performed without undue
experimentation.
Derivatization with bifunctional agents is useful for preparing intramolecular aggregates
of the selectin ligand glycoprotein with polypeptides as well as for cross-linking the selectin
ligand glycoprotein to a water insoluble support matrix or surface for use in assays or affinity
purification. In addition, a study of interchain cross-links will provide direct information on
conformational structure. Commonly used cross-linking agents include 1 ,1-bis(diazoacety|)
phenylethane, glutaraldehyde, N-hydroxysuccinimide esters, homobifunctional imidoesters,
and bifunctional maleimides. Derivatizing agents such as methyll(p-
azidophenylldithiolpropioimidate yield photoactivatabie intermediates which are capable of
forming cross-links in the presence of light. Alternatively, reactive water insoluble matrices
such as cyanogen bromide activated carbohydrates and the systems reactive substrates
described in U.S. patent Nos. 3,959,642; 3,969,287; 3,691,016; 4,195,128; 4,247,642;
4,229,537; 4,055,635; and 4,330,440 are employed for protein immobilization and cross-
linking.
Certain post-translational modifications are the result of the action of recombinant host
cells on the expressed polypeptide. Glutaminyl and aspariginyl residues are frequently post-
translationally deamidated to the corresponding glutamyl and aspartyl residues. Alternatively,
these residues are deamidated under mildly acidic conditions. Either form of these residues
falls within the scope of this invention.
Other post-translational modifications include hydroxylation of proline and lysine,
phosphorylation of hydroxyl groups of seryl or threonyl residues, methylation of the a-amino
groups of lysine, arginine, and histidine side chains lT.E. Creighton, Proteins: Structure and
Molegular Properties, W.H. Freeman & C0,, San Francisco, pp. 79-86 (1983)].
Other derivatives comprise the novel peptides of this invention covalently bonded to
a nonproteinaceous polymer. The nonproteinaceous polymer ordinarily is a hydrophilic
synthetic polymer, i.e. a polymer not otherwise found in nature. However, polymers which
exist in nature and are produced by recombinant or in vitro methods are useful, as are
polymers which are isolated from nature. Hydrophilic polyvinyl polymers fall within the scope
of this invention, e.g. polyvinylalcohol and polyvinylpyrrolidone. Particularly useful are
polyvinylalkylene ethers such a polyethylene glycol, polypropylene glycol.
The selectin ligands may be linked to various nonproteinaceous polymers, such as
polyethylene glycol, polypropylene glycol or polyoxyalkylenes, in the manner set forth in U.S.
Patent Nos. 4,640,835: 4,496,689; 4,301,144; 4,670,417; 4,791,192 or 4,179,337.
The selectin ligands may be entrapped in microcapsules prepared, for example, by
coacervation techniques or by interfacial polymerization, in colloidal drug delivery systems
(e.g. liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsulesl,
or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical
Sciences, 16th Edition, Osol, A., Ed. (1980).
l_. Selectin Ligand ; Stable Plasma Protein Chimeras
A selectin ligand sequence can be linked to a stable plasma protein sequence as
hereinbefore defined. The stable plasma protein sequence may, for example. he an
immunoglobulin constant domain sequence. The resultant molecules are commonly referred
to as selectin ligand-immunoglobulin chimeras.
ln a preferred embodiment, the C-terminus of a sequence which contains the binding
sitelsl for a selectin, is fused to the N-terminus of the C-terminal portion of an antibody (in
particular the Fc domain). containing the effector functions of an immunoglobulin, e.g.
immunoglobulin G,. it is possible to fuse the entire heavy chain constant region to the
sequence containing the selectin binding sitelsl. Hoi/vever, more preferably, a sequence
beginning in the hinge region just upstream of the papain cleavage site (which defines lgG Fc
chemically; residue 216, taking the first residue of heavy chain constant region to be 1
._J_. Q_f_ IE Selectin Ligands
The selectin ligand may be recovered and purified from recombinant cell cultures by
known methods, including ammonium sulfate or ethanol precipitation, acid extraction, anion
or cation exchange chromatography, hydroxyapatite chromatography, immunoaffinity
chromatography and lectin chromatography. Other known purification methods within the
scope of this invention utilize reverse-phase HPLC chromatography using anti-selectin ligand
antibodies are useful for the purification of the ligands of the present invention.
A particularly advantageous purification scheme, specifically developed for the
purification of the L-selectin ligand, will be described in Example 1. This method takes
advantage of a unique selectin receptor-immunoglobulin chimera (referred to as L-selectin-
|gG), produced by recombinant methods, which is able to precipitate the corresponding
(sulfate-labeled) ligand.
; Theragegtig Cgmgositions
The selectin ligands of the present invention can be used to block the binding of a
corresponding selectin receptor to its native ligand. For example, the L-selectin ligand
effectively blocks the binding of an L-selectin receptor on a circulating leukocyte to its native
ligand on an endothelial cell. This property is useful for treating a symptom or condition
associated with excessive binding of circulating leukocytes to endothelial cells, such as
inflammation, associated with rheumatoid arthritis, psoriasis, multiple sclerosis, etc.
The selectin ligands of the present invention can be formulated according to known
methods to prepare pharmaceutically useful compositions, whereby the ligand is combined
in admixture with a pharmaceutically acceptable carrier. Suitable carriers and their
formulations are described in Reminqton's Pharmaceutical Sciences, 16th ed., 1980, Mack
Publishing Co., edited by Oslo et al. These compositions will typically contain an effective
amount of the ligand, for example, from on the order of about 0.5 to about 10 mg/ml,
together with a suitable amount of carrier to prepare pharmaceutically acceptable
compositions suitable for effective administration to the patient. The ligands may be
administered parenterally or by other methods that ensure its delivery to the bloodstream in
an effective form.
Compositions particularly well suited for the clinical administration of the ligands used
to practice this invention include sterile aqueous solutions or sterile hydratable powders such
as lyophilized protein. Typically, an appropriate amount of a pharmaceutically acceptable salt
is also used in the formulation to render the formulation isotonic.
-3 2-
Dosages and desired drug concentrations of pharmaceutical compositions of this
invention may vary depending on the particular use envisioned.
L Monoclonal Antibodies
Monoclonal antibodies are obtained from a population of substantially homogeneous
antibodies, i.e., the individual antibodies comprising the population are identical except for
possible naturally occurring mutations that may be present in minor amounts. Thus, the
modifier "monoclonal" indicates the character of the antibody as not being a mixture of
discrete antibodies.
For example, the monoclonal antibodies of the invention may be made using the
hybridoma method first described by Kohler 8: Milstein, Nature _2fi:495 (1975), or may be
made by recombinant DNA methods [Cabilly, gt _a_l., U.S. Pat. No. 4,816,567].
In the hybridoma method, a mouse or other appropriate host animal, such as hamster
is immunized with the selectin ligand protein by subcutaneous, intraperitoneal, or
intramuscular routes to elicit lymphocytes that produce or are capable of producing antibodies
that will specifically bind to the protein used for immunization. Alternatively, lymphocytes
may be immunized l_l1flLf_Q. Lymphocytes then are fused with myeloma cells using a suitable
fusing agent, such as polyethylene glycol, to form a hybridoma cell [Goding, Monoclonal
Antibodies: Principles and Practice. pp.59-103 (Academic Press, 1986)].
The hybridoma cells thus prepared are seeded and grown in a suitable culture medium
that preferably contains one or more substances that inhibit the growth or survival of the
unfused, parental myeloma cells. For example, if the parental myeloma cells lack the enzyme
hypoxanthine guanine phosphoribosyl transferase IHGPRT or HPRTl, the culture medium for
the hybridomas typically will include hypoxanthine, aminopterin, and thymidine (HAT
medium), which substances prevent the growth of HGPRT-deficient cells.
Culture medium in which hybridoma cells are growing is assayed for production of
monoclonal antibodies directed against TNFR1. Preferably, the binding specificity of
monoclonal antibodies produced by hybridoma cells is determined by immunoprecipitation or
by an jg _yjt_r_g binding assay, such as radioimmunoassay lRlA) or enzyme-linked
immunoabsorbent assay (ELlSA).
The affinity of the monoclonal antibody for binding the corresponding ligand can, for
example, be determined by the Scatchard analysis of Munson & Pollard, Anal. Biochem.
1_O_Z:22O (1980).
After hybridoma cells are identified that produce antibodies of the desired specificity,
affinity, anr*'or activity, the clones may be subcloned by limiting dilution procedures and
grown by s. idard methods. Goding, Monoclonal Antibodies: Principles and Practice, pp.59-
104 (Academic Press, 1986). Suitable culture media for this purpose include, for example,
Dulbecco's Modified Eagle's Medium or FlPMl—1640 medium. In addition, the hybridoma cells
may be grown i_n y_i_\;g as ascites tumors in an animal.
The monoclonal antibodies secreted by the subclones are suitably separated from the
culture medium, ascites fluid, or serum by conventional immunoglobulin purification
procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel
electrophoresis, dialysis, or affinity chromatography.
Typically such non-immunoglobulin polypeptides are substituted for the constant
domains of an antibody of the invention, or they are substituted for the variable domains of
one antigen-combining site of an antibody of the invention to create a chimeric bivalent
antibody comprising one antigen-combining site having specificity for a selectin ligand and
another antigen-combining site having specificity for a different antigen.
Chimeric or hybrid antibodies also may be prepared i_nLrg using known methods in
synthetic protein chemistry, including those involving Erosslinking agents. For example,
immunotoxins may be constructed using a disulfide exchange reaction or by forming a
thioether bond. Examples of suitable reagents for this purpose include iminothiolate and
methylmercaptobutyrimidate. '
For diagnostic applications, the antibodies of the invention typically will be labeled with
a detectable moiety. The detectable moiety can be any one which is capable of producing,
either directly or indirectly, a detectable signal. For example, the detectable moiety may be
a radioisotope, such as ‘H, “C, ”P, “S, or "‘I, a fluorescent or chemiluminescent compound,
such as fluorescein isothiocyanate, rhodamine, or luciferin; radioactive isotopic labels, such
as, e.g., T2‘), "P, “C, or “H, or an enzyme, such as alkaline phosphatase, beta-galactosidase
or horseradish peroxidase.
The antibodies of the present invention may be employed in any known assay method.
such as competitive binding assays, direct and indirect sandwich assays, and
immunoprecipitation assays. Zola, Monoclonal Antibodies: A Manual of Technigues, pp.147-
(CRC Press, lnc., 1987).
Competitive binding assays rely on the ability of a labeled standard (which may be a
selectin ligand or an immunologically reactive portion thereof) to compete with the test
sample analyte (selectin ligand) for binding with a limited amount of antibody. The amount
of selectin ligand in the test sample is inversely proportional to the amount of standard that
becomes bound to the antibodies. To facilitate determining the amount of standard that
becomes bound, the antibodies generally are insolubilized before or after the competition, so
that the standard and analyte that are bound to the antibodies may conveniently be separated
from the standard and analyte which remain unbound.
Sandwich assays involve the use of two antibodies, each capable of binding to a
different immunogenic portion, or epitope, of the protein to be detected. In a sandwich
assay, the test sample analyte is bound by a first antibody which is immobilized on a solid
support, and thereafter a second antibody binds to the analyte, thus forming an insoluble
three part complex. David & Greene, U.S. Pat No. 4,376,110. The second antibody may
itself be labeled with a detectable moiety (direct sandwich assays) or may be measured using
an anti-immunoglobulin antibody that is labeled with a detectable moiety (indirect sandwich
assay). For example, one type of sandwich assay is an ELISA assay, in which case the
detectable moiety is an enzyme.
The invention will further be illustrated by the following non-limiting examples.
.35.
(ll. EXAMPLES
EXAMPLE 1
identification of Surface Glycoproteins on Endothelial Cells
Recognized by L-selectin J
This example shows that recombinant L-selectin selectively binds “S0.-labeled
macromolecules from lymph nodes. In particular, two sulfated, fucosylated and sialylated
glycoproteins have been identified.
A. Metabolic Labeling of Organs with “S-sulfate
B. Identification of the Components Adsorbed to L-selectin-lgG Beads
Affi-Gel Protein A (10 ,ul packed beads) was incubated with 30 pgof either L-selectin-
lgG (WO 91/08298 published 13 June 1991), CD4-lgG (prepared according to Capon et al.,
N_at_i_:;e 3_37_:525 (1989) or human lgG, (calbiochem, La Jolla, CA) in 1 ml of PBS rocking
overnight at 4°C. The beads (referred to as L-selectin-lgG beads, CD4-lgG beads and hulgG-
beads) were washed 3X in PBS and once with Iysis buffer. The CD4-lgG and hulgG beads
were used as controls.
The precleared lysate described in Section A, above, was centrifuged at 10,000 x g
for 10 sec, CaCl, was added to the supernatant at a‘ final concentration of 5 mM, and the
supernatant was mixed immediately with either L-selectin-lgG beads, CD4-lgG beads C’
huIgG—beads (typically 200 ,ul of precleared lysate per 10 pl packed beads), and incubated for
4 hr at 4°C on a rocker. The beads were washed 6X with lysis buffer, transferred to a new
tube, and washed once more with lysis buffer.
The materials bound to the L-selectin-lgG beads were solubilized by boiling in SDS in
the presence of 2-mercaptoethanol, electrophoresed on SDS-polyacrylamide gels (9 or 10%)
and subjected to fluorography with ENTENSIFY or EN“?-lANCE (NEN). By fluorography, the
50 kD component tended to be more diffuse with ENTENSlFY than EN°HANCE. In the
reprecipitation experiment, the SDS-solubilized sample was electrophoresed on a 7.5% SD8-
gel with prestained standards (BioRad, high range) as markers. The region around 50 kD on
the gel was excised by utilizing prestained ovalbumin (49.5 kDl as a position marker, and the
protein electroeluted lBioRad model 422) into Laemmli running buffer at 60 mA overnight.
The eluate was concentrated and the buffer was exchanged into 10 mM CAHPS in PBS on
a Centricon 30 unit (Amicon, Danvers, MA), followed by incubation with L-selectin-lgG beads
CD4-lgG or hulgG beads as described above. For the analysis of crude Iysate, 200 pl of the
precleared lysate was precipitated with cold acetone (80% v/vl and then subjected to
electrophoresis as above.
L-selectin-lgG beads precipitated a diffuse 50 kD component (apparent molecular
Weight range is 50 RD - 58 kDl from [°‘S]-sulfate-labeled mesenteric lymph nodes lMLNl or
peripheral lymph nodes (PM. A band of ~90 RD (83 kD - 102 km, relatively minor in terms
of sulfate incorporation, was also observed in most analyses. ln control precipitations, CD4-
IgG and hulgG beads did not recognize the 50 kD major component or the 90 kD component
in the lysates. When crude lysates were directly analyzed, the 50 kD component represented
the major constituent among several other bands. The tissue distribution of the 50 kD
component was further examined by applying the identical protocol for (“SI sulfate-labeling
and precipitation with LHFl lgG to a number of organs. Among lymphoid tissues, only
peripheral lymph nodes and mesenteric lymph nodes showed the 50 kD and 90 kD bands,
while Peyer's patches, spleen, and thymus were negative for both. Non-lymphoid organs
such as kidney, liver, cerebrum, and cerebellum were also completely negative.
L-selectin-lgG beads precipitated the 50 kD component when calcium was present, but
not in its absence. The specificity of the interaction was further examined with the use of
MEL-14 mAb. Preincubation of L-selectin-lgG beads with this antibody completely blocked
the binding of the 50 kD band to the beads, whereas a class-matched control antibody (anti-
CD45l had no effect. Fucoidin completely blocked the precipitation of the 50 kD component
by L-selectin-lgG beads, while control polysaccharides lchondroitin sulfate B, chondroitin
sulfate A, keratan sulfate) were completely inactive. Further, the presence of PPME
significantly reduced the intensity of the 50 kD band, although a relatively high concentration
was required. A control yeast mannan lmnn 2) had no effect at the same concentration. The
precipitation of the minor 90 kD band by L-selectin-lgG beads was also calcium dependent,
inhibitable by MEL-14 mAb, and blocked by fucoidin and PPME.
Finally, sialidase treatment of the glycoproteins was found to inhibit binding by L-
selectin-lgG. Thus, sialic acid on the glycoproteins is apparently essential for binding. This
result is in agreement with previous characterizations of interactions between selectins and
their ligands.
EXAMPLE 2
Purification of the 50 kD L-selectin ligand for cloning
and sequence determination
The work described in Example 1 demonstrated that the L-selectin-lgG chimera could
be utilized to biochemically characterize the ~ 50 kD sulfated endothelial ligand produced by
peripheral and mesenteric lymph nodes. Further work has demonstrated that this ligand is
readily shed into the medium when peripheral lymph nodes lPLN) are placed into organ culture
(S. Watso_n—unpublished observations). Thus, the initial step in the purification of the L-
selectin ligand for sequence determination was to produce large quantities of medium
conditioned by murine PLN. A second observation that allowed for a dramatic purification
was that L-50 kD sulfated L-selectin ligand was soluble after treatment of conditioned
medium with chloroform-methanol. This step resulted in a >350 fold purification of the
sulfated ligand. The next purification step consisted of a wheat germ agglutinin affinity
column, which took advantage of the apparently high content of carbohydrate in this ligand.
The final purification step utilized an L-selectin-lgG chimera affinity column to purify the
ligand. This final step assured that the material contained within the ~50 l
correspond to a glycoprotein that could bind with relatively high affinity to L-Selectin.
Mesenteric or peripheral (cervical, brachial, and axillary) lymph nodes were collected
from 8wk-old female ICR mice. Mice were killed and their mesenteric lymph nodes were
removed. Typically, a single batch of conditioned medium was made from the mesenteric
nodes of 30 mice. Occasionally, a small number (approximately 5% of the total lymph node
weight) of peripheral lymph nodes were also added. The nodes were cut into approximately
1-mm-thick slices with a razor blade and the slices were added to the standard cell culture
medium RPMI-1640 supplemented with 25 mM HEPES buffer, 1 Ulml penicillin and 1 pg/ml
streptomycin in a 100—ml cell culture bottle. The ratio ofmedium to nodes was 6 ml/30
mesenteric lymph nodes.
The culture bottle was placed in a 37°C incubator. After 4 hours, the medium was
poured into a 15-ml conical tube and centrifuged at 500 x g for 10 minutes to remove large
tissue debris. The supernatant was centrifuged again in a 15-ml Corex tube at 20,000 x g
for 15 minutes. The resultant supernatant was first poured through Nitex screen to remove
fatty particles that do not pellet during centrifugation, and was then snap-frozen with liquid
nitrogen and stored at -20°C.
For the purpose of monitoring the protein purification scheme, “S0,,-labeled Sgp5O
was added to the conditioned medium prepared as hereinabove described. This material was
prepared by labeling 5 mice mesenteric lymph nodes in 1 ml of the above-described culture
medium with 0.5 mCi Na"SO, llCN). After 4 hours, the conditioned cell culture medium was
removed and centrifuged in a microfuge for 10 minutes. The supernatant was removed and
precleared by adding to 100 pl packed protein A—agarose beads (Zymed Corp.), and rocking
-3 8-
overnight at 4°C. The precleared medium was added to a 3 ml covalently crosslinked LEC-
lgG-protein A-agarose (LEC x protein A-agarose) column prepared with 10 mg L-selectin-lgG
per 1 ml packed protein A-agarose (Zymed) following the procedure outlined on pages 522-
523 of Antibodies. A Laboratory Manual (1988) Harlow and Lane, Cold Spring Harbor
Laboratory. After rocking for 6 hours to overnight with L-selectin x protein A-agarose, the
column was washed with 10 volumes Dulbecco’s phosphate-buffered saline (PBS) and the
purified material (50 kD L-selectin ligand, a.k.a. G|yCAM) was eluted with 10 ml 4 mM EDTA
in PBS. This material was concentrated on a Centricon 30 (Amicon Corp.) to a final volume
of approximately 100 pl. About 60,000 cpm of material were obtained.
To produce purified protein for microsequencing analysis, four batches (approximately
120 mice) of conditioned medium (24 ml) were thawed. 50 pl of “S04-labeled Sgp50
(32,000 cpm) was added. Nine volumes (216 ml) of chloroform:methanol (2:1) was added
and rocked in 50-ml conical tubes for 30 minutes at room temperature and centrifuged at 500
x g for 20 minutes. The upper aqueous layer was collected and the "interface" layer was
recentrifuged to extract as much aqueous layer as possible. The chloroformzmethanol
extraction was repeated. in order to see an aqueous layer, approximately 20 ml of PBS was
added. The aqueous layer was collected and residual chloroformzmethanol evaporated by
stirring the aqueous layer for 3 hours in a one-liter beaker in a warm water bath in the fume
hood. The material, now called
dialyzed against PBS for 4 hours. In a similar preparation, 1 385-fold purification was
achieved. The dialyzed
wheat germ agglutinin (WGA)-agarose gel (Vector Laboratories). The gel was collected in a
column, washed with 40 ml PBS and eluted with 0.2 M n-acetylglucosamine in PBS. In a
similar experiment, an additional 4.4-fold purification was achieved. This material, containing
approximately 15000 cpm representing the equivalent of 60 mice, was concentrated on a
Centricon 30, and run on a 10% SDS-gel under standard Laemmli procedures. In a similar
experiment, a final purification on LEC x protein A-agarose yielded an overall 60606—fold
purification. The protein was then electroblotted in a BioRad miniblotter (250 mA, constant
current for 2 hours) onto ProBlott membrane (Applied Biosystems lncorp.l. The membrane
(blot) was stained and destained with Coomassie R-250 following the manufacturer's
recommendation. The blot was air-dried and autoradiography performed with Kodak XAR
film.
The purified material was then subjected to gas-phase microsequencing.
EXAMPLE 3
Protein Sequence Determination
The polypeptide sequence was determined by gas-phase microsequencing of the
material purified as described in Example 2. The protein eluted from the L-Selectin-lgG
affinity column was run on a 10% SDS-gel, electroblotted onto a Problott membrane (Applied
amino acids.
Biosystems |nc.),~ stained with Coomassie R-250 and destained. The blot was air-dried and
exposed to Kodak XAR film to detect the position of the sulfate labelled ligand. This region
of the gel was cut out and subjected to gas—phase microsequencing. Sequencing was
essentially performed as hereinbefore described.
Polypeptide sequencing revealed an unambiguous stretch of 25 amino acids at
approximately the 5 pM level (Figure 38}.
EXAMPLE 4
cDNA Cloning and Sequence Analysis of the -50 kD L-Selectin
Ligand
A murine peripheral lymph node cDNA library was constructed using an |nvitroGen
cDNA library kit and poly A + RNA isolated from murine peripheral lymph nodes. A redundant
oligonucleotide probe pool was derived from residues 9-17 of the N-terminal sequence
lOMKTOPMDA) using degenerate codons selected on the basis of the mammalian codon
usage rule. Codons were CAG, ATG, AAG, AAA,'ACA, ACT, ACC, CCA, CCT, CCC, GAT,
or GAC. Only GC was used for the 5' Ala codon. The 26-mer oligonucleotide was ”P
labeled by polynucleotide kinase and hybridized to duplicate nitrocellulose filters derived from
plates containing 1 million gT1O bacteriophage in 20% formamide, 5X SSC (150 mM
CaCl, 15 mM trisodium citrate). 50 mM sodium phosphate lpH7.B), 5X Denhardt's solution,
% dextran sulfate and 20 micrograms per ml denatured, sheared salmon sperm DNA at
42°C overnight. The filters were washed in 1X SSC, 0.1% SDS at 42°C twice for 30
minutes and autoradiographed at -70°C overnight. A single duplicate positive. phage was
plaque purified, and the Eco R1 insert was subcloned into the pGEM vector. The entire
nucleotide sequence of both strands was obtained by supercoin sequencing with the
Sequenase kit. For jg E hybridization and Northern blot analysis, a polymerase chain
reaction fragment lacking the poly A tail was synthesized then subcloned into the pGEM
vector (PROMEGA). The nucleotide sequence of the encoded cDNA is shown in Figure 4.
The clone contained a short labout 600 bp) cDNA with a single open reading frame of 151
A "Kozak box" (CCACCATGA) was found surrounding the first encoded
methionine iKozak, M. Cell Biology1_1_5:887 (1991)i. This methionine was followed by a 19
amino acids long, highly hydrophobic sequence that appears to function as a signal sequence
for translocation of the protein into the secretory pathway. This region is followed by a
sequence corresponding almost exactly to that determined by N-terminal sequencing of the
L-selectin-IgG bound material. The signal sequence-processed 132 amino acid protein is
extremely rich in serine and threonine, with about 29% of the encoded amino acids
corresponding to these residues.
Perhaps more interestingly, these serine and threonine residues were found to be
clustered in two regions of the glycoprotein (Figure 3D). Region I (residues 42-63) was found
to contain 12 serine or threonine residues (~55%) while region ll (residues 93-122) was
.40-
Examination of the C-terminus of the protein encoded by this cDNA revealed a mildly
hydrophobic domain, but no obvious trans-membrane anchoring motif. While it is possible
that this region corresponds to a signal directing the addition of a phosphatidyl inositol (Pl)
tail, treatment of lymph node sections with phosphatidyl inositol phospholipase C lP|PLC)
does not appear to remove the ligand from the endothelium (M. Singer, S. Watson, R.
Mebius-unpublished observations). While this result does not disprove the possibility that the
~50 kD ligand associates with the cell surface using a PI tail, it suggests that other possible
linkages to the cell surface may be utilized by this glycoprotein. Examination of the C-
terminal 21 amino acids by a program that searches for amphipathic helices reveals that the
C-terminus of this glycoprotein encodes a highly significant amphipathic helix (Figure 3C).
with one face of this potentially helical region containing apolar residues while the other face
contains polar residues [J. Mgl. Biol. £11155 (198411.
EXAMPLE 5
Production of Antibodies Against Peptides
boosted rabbits were collected (the rabbit polyclonal antipeptide sera are now designated
CAMO1, CAMO2, CAM05l, and each sera was tested for its ability to immunoprecipitate
.41-
sulfate labeled L-selectin ligand that was purified by binding to the L-selectin-lgG chimera as
described above.
To verify that the cloned protein is the same as the "S-labeled material purified from
conditioned medium with the L-selectin lgG chimera, immunoprecipitation of L-selectin-lgG
purified “S-labeled material was performed. The following procedure was used for two
separate experiments. For the preparation of immunoprecipitation beads, 25 pl packed
protein A-Sepharose beads (Zymed Laboratories) + 25 pl rabbit serum + 350 pl PBS are
rocked together in a microfuge tube for 3 hours, 4°C. Each tube is washed 3 times with PBS
60 pl of PBS
containing approximately 6,000 cpm of L-selectin-lgG purified “S-labeled material is added.
to remove unbound immunoglobulin and only the 25 pl beads remains.
This is incubated on ice for 3 hours, flicking the tube every 15 minutes. After 3 hours, the .
microfuge tube is spun to pellet the beads. 45 pl of supernatant is taken off and mixed with
pl 4X Laemmli sample buffer and boiled for SDS-PAGE analysis. The pelleted beads are
washed 3 times with PBS, transferred to a new tube, and supernatant decanted to leave 45
pl final volume in tube. 15 pl 4X Laemmli sample buffer is added and the tubes are boiled for
SDS-PAGE analysis. This SDS-gel run was under reducing conditions. lmmunoglobulin heavy
chain runs at 50 kD under reducing conditions and the labeled band is compressed. in this
experiment, none of the preimmune sera interact with the label, whereas, CAMO1 and
CAM05 have partial effects and CAM02 totally immunoprecipitates the band. This
experiment was repeated with CAM02 with the following differences. The gel was run under
(We have
previously established that the L-selectin-lgG purified “S-labeled material does not change
non-reducing conditions so that the 50 kD band would not be compressed.
mobility in an SDS-gel under reducing conditions.) Also, for one tube, the CAM02 antibody
coated-beads were preincubated with 1 mg/ml CAM02 peptide for 30 minutes on ice in order
to show specificity of the antibody-antigen interaction. Finally, an irrelevant control peptide
antibody against the C-terminus peptide of L-selectin (called ROSY 18), also prepared by
Caltag using similar protocols, was tested. Both gels were subjected to fluorography with
Enhance (New England Nuclear) and autoradiography with Kodak Xar film. CAM02
completely immunoprecipitates the L-selectin-lgG purified “S-labeled material, CAM02
preimmune and ROSY 18 have no effect. The free CAM02 peptide blocks the specific
immunoprecipitation. The results are shown in Figures 5A and B.
EXAMPLE 6
Expression of the L-Selectin Ligand
Figure 6 shows a Northern blot analysis of the mFiNA encoding the ~ 50 kD L-selectin
ligand. As can be seen in Figure 6A, the mRNA is encoded in the poly A+ fraction and
corresponds to a discrete band of ~O.7 kD. The sharpness of the band argues against a
significant level of alternative RNA splicing, and rescreening of the murine PLN cDNA library
with the isolated ligand clone has not revealed any other spliced forms of the message.
lnduction of an inflammatory response in the region drained by a lymph node shows a relative
decrease in the amount of mRNA encoding the ligand, presumably due to the large
contribution of polyA + mRNA from newly migrating lymphocytes. This result suggests that
the ligand does not appear to be dramatically induced in the PLN HEV during inflammation,
although it is difficult to make quantitative conclusions from this experiment. Inspection of
the expression of this mRNA in different regional lymph nodes demonstrates that it is
expressed in all regional PLN that we have examined (Figure 6Bl.
Analysis of the expression of the mRNA encoding the L-selectin ligand in a number of
different lymphoid and non—lymphoid tissues reveals that this sequence is expressed in a
highly tissue-specific manner. Figure 6C shows that the mRNA corresponding to the ligand
is expressed strongly in both mesenteric and peripheral lymph nodes. This agrees with
previous work which demonstrated that the sulfate-labeled ligand was found to be expressed
only in these two organs. The message is also expressed at significant levels in the lung and
at very low levels in the Peyer's patches. The mRNA is not detectable in a number of non-
lymphoid organs nor is it found in two other lymphoid organs: spleen and thymus. This latter
result strongly suggests that the ligand may be significantly expressed in only a subset of the
vasculature: i.e. the HEV found in peripheral lymphoid tissues.
Peripheral lymph nodes and sections of small intestine having a Peyer's patch were harvested
from mice, fixed in paraformaldehyde followed by sucrose immersion. Tissues were
embedded in OCT compound (Miles Scientific), frozen in isopentane and sectioned in 8 micron
sections. The sections were thaw-mounted on Vectabond-coated slides (Vector
Laboratories). “S-labeled RNA probes were generated in the sense and anti-sense
orientations using previously described methods (Melton et al. 1984). For hybridization,
sections were treated sequentially with 4% paraformaldehyde (10 min.), proteinase K (1
microgram/ml, 10 min.) followed by prehybridization with 100 microliters of hybridization
buffer (50% formamide. 0.03 M NaCl, 20 mM Tris-HCl, 5 mM EDTA, 1X Denhardt's solution,
% Dextran Sulfate, 10 mM dithiothreitoll at 42°C for 2 Hrs. Probes were added at a final
concentration of 8 x 105 cpmlml and then incubated overnight at 55°C. Slides were washed
with 2X SSC containing 10 mM beta mercaptoethanol (BME), 1 mM EDTA followed by a 30
minute treatment (20 micrograms/ml for 30 minutes). A high stringency wash consisting of
0.1 X SSC containing EDTA and BME was done at 55°C for 2 hrs. Slides were washed in 0.5
X SSC, dehydrated in increasing concentrations of ethanol and vacuum dessicated. Slides
were dipped in NTB2 nuclear emulsion (Kodak) and exposed for up to 5 weeks. Slides were
developed, counterstained with hematoxylin and eosin. Negative controls consisted of
hybridization of serial sections with sense probes. As can be seen in Figure 7, the antisense
strand encoded by the isolated ligand cDNA clone clearly hybridizes to the HEV of peripheral
lymphoid tissue, while the sense strand shows no significant hybridization. This result clearly
demonstrates that the mRNA corresponding to the ligand CDNA is synthesized by HEV cells,
consistent with previous immunohistochemical data demonstrating the localization of the L-
selectin ligand to this region of the mesenteric and PLN.
The use of a mucin-like glycoprotein as a scaffold for carbohydrate presentation to a
seleotin makes sense when viewed in the context of what is currently known about mucin
structure. Previous investigations into the structures of highly O-linked glycoproteins such
as mucins have revealed that these molecules tend to be highly extended, somewhat rod—like
molecules. For example, the leukocyte surface mucin Ieukosialin lsialophorin, CD43) lCyster
et al. 1991, flp_r__a_, Fukuda 1991. flag), has been demonstrated to form a rigid, rod-like
structure, and physico—chemical analyses of other mucins have demonstrated similar rod-like
conformations, particularly in the highly O-glycosylated regions (Harding, S.E., Advances in
Carbohydrate Chemistry and Biochemistry 4_7:345 Academic Press, Inc. (1989), Jentoft, N.,
E _1_5_:291 (1990)). ln addition, other non-mucin proteins, such as decay accelerating
factor (DAF) and the low density lipoprotein (LDL) receptor contain highly O-linked domains
near the cell surface that appear to form rod-like domains that may function to extend the
receptors through the glycocalyx (Jentoft 1990, sg_;>r_al. This rod-like structure is exactly
what would be expected of a molecule whose role is to present carbohydrates to the lectin
domain of a seleotin. As shown in the model illustrated in Figure 6, the L-selectin ligand may
be thought of as a “bottle brush" that extends into the lumen of the HEV. This would allow
for a large number of O-linked carbohydrate ligands (the bristles on the brush) to be
appropriately presented to the lymphocyte surface—localized L-selectin lectin domain, thus
mediating adhesion to the endothelium. The apparent clustering of these carbohydrates into
2 domains on the ligand suggests that they may be presented in a polyvalent manner to
enhance the binding avidity of the lymphocyte-HEV adhesive interaction. The mucin-like
nature of the L-selectin ligand could thus function to present polyvalent carbohydrate ligands
to the L-selectin lectin domain via an extended, rod-like platform. If accurate, this would
define a new mechanism of cell adhesion in the immune system.
J. Qgll Biol. _1;;, 1213 (1991), Streeter et al., J. Qell Bigl, 1_0_7, 1853 1988b, Woodruff et
al., Anng. Rev, lmmunol. 5, 201 (1987). These results are consistent with the possibility that
regional trafficking is, at least in part, controlled by the transcriptional activation of the ligand
mRNA described here, and suggest that exogenous factors may regulate L-selectin—mediated
adhesion by controlling the transcription of the ligand gene. Of course, the protein backbone
of the ligand is insufficient to mediate L-selectin adhesion, and it is possible that the genes
controlling the glycosyl-transferases involved in making the carbohydrate ligandlsl found on
this backbone may also be transcriptionally regulated. This latter possibility is now testable
by investigating the activity of the ligand glycoprotein produced by expression of the cDNA
described here in non-HEV cells. Another level of regulation may involve the mechanisms by
which the - 50 kD ligand receives the appropriate L-selectin-specific carbohydrate side chains
while other 0-linked glycoproteins do not. The possibility that the L-selectin ligand described
here can be ectopically expressed in chronic or acute inflammatory sites to mediate
lymphocyte or neutrophil trafficking remains to be investigated (Watson et al., _l\_la_t_t_:;g
;4_9:164 (1991)). it is possible that the extremely low level of ligand mFlNA expression
detected in the Peyer’s patch is an indication of such regulatable ectopic expression.
While it is clear that the ~ 50 kD ligand described here readily adheres to L-selectin via
protein-carbohydrate interactions, the mechanism by which this ligand associates with the
endothelial cell surface remains to be defined. The rapid shedding found here could be an
artefact of organ culture, but other data demonstrating that an active shed form of the ligand
can be purified from bovine (J. Gilbert-unpublished observations) or murine (8. Watson-
unpublished observations) serum suggest that this ligand may be shed i_r;1iy_g_. A number of
other cell surface adhesion molecules, including L- and P-selectins, Johnston et al., _(;_e_ll 5_6,
1033 (1989)) and lCAM l lRothlein et al., J. lmmunol. _1_4_7:3788 (1991)). have been found
to be shed, and it appears that in many cases the shedding is of physiological importance.
.45-
The ~50 kD L-selectin ligand is the fourth type of molecule that is involved with cell
adhesion in the immune system: 1) the leukocyte integrins, 2) their ligands, the
immunoglobulin (lg) superfamily members, 3) the selectins and 4) the ~50 kD L-selectin
ligand. The integrins, lg superfamily members, and selectins have all been found to comprise
families containing a diversity of related molecules. Because of the characteristics of the
ligand described here, we propose to replace the cumbersome nomenclature used throughout
.46.
this application with the more descriptive term, GLYCAM l lGLYcosylation dependant Cell
Adhesion Molecule).
Claims (28)
1. An isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide having a sterical structure allowing for the presentation of a selectin-binding moiety having the ability to bind an L-selectin, and wherein the nucleotide sequence is able to hybridize under low stringency conditions to the complement of a nucleotide sequence encoding a protein having the amino acid sequence of Figure 4.
2. The nucleic acid molecule of claim 1 comprising a nucleotide sequence encoding a selectin ligand protein having an amino acid sequence greater than about 40% homologous with the amino acid sequence shown in Figure 4.
3. An isolated nucleic acid molecule which is a cDNA clone comprising a nucleotide sequence encoding amino acids 42 to 63, or 93 to 122 of the amino acid sequence shown in Figure 4.
4. The nucleic acid molecule of claim 1 comprising a nucleotide sequence encoding an L-selectin ligand.
I 5. The nucleic acid molecule of claim 4_ comprising the coding region of the nucleotide sequence shown in Figure 4.
6. The nucleic acid molecule of claim 1 fused to a nucleotide sequence encoding an immunoglobulin constant domain.
7. The nucleic acid molecule of claim 6 wherein the immunoglobulin’ is lgG‘l, lgG2, lgG3, lgG4, lgA, lgE, lgD or lgM.
B. The nucleic acid molecule of claim 5 further comprising a promoter operably linked to the coding region of the nucleotide sequence shown in Figure 4. 20
9. An expression vehicle comprising and capable, in a recombinant host cell, of expressing a nucleotide sequence of claim 1 operably linked to control sequences recognized by a host cell transformed with the vehicle.
10. A host cell transformed with the expression vehicle of claim 9.
11. The host cell of claim 10 which is an eukaryotic cell.
12. The host cell of claim 11 which is a mammalian cell.
13. The host cell of claim 12 which is from the human embryonic kidney cell line 2933.
14. A method for culturing the host cell of claim 10 in A suitable culture medium to express an L-selectin ligand.
15. The method of claim 14 further comprising recovering said L-selectin ligand from the culture.
16. An isolated L-selectin ligand polypeptide comprising the amino acid sequence of Figure 4.
17. The L-selectin ligand polypeptide of claim 16 which is a glycoprotein.
18. The glycoprotein of claim 17 which has a_ molecular weight of about 50 RD.
19. An isolated L-selectin ligand polypeptide ‘from an animal origin other than mouse, or variant of said polypeptide, comprising an amino acid sequence encoded by a nucleic acid able to hybridize under low stringency conditions to the 20 complement of a nucleotide sequence encoding the protein having the amino acid sequence shown in Figure 4.
20. The polypeptide of claim 19 wherein the low stringency conditions are overnight incubation at 37°C in a solution comprising: 20% forrnamide. 5 x SSC (150 mM NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5 x Denhardt's solution. 10% dextrane sulfate, and 20 pg/ml denatured, sheared salmon spenn DNA.
21. The polypeptide of claim 19 which is a native L-selectin ligand substantially free of other proteins of the same animal species in which it naturally OCCUFS.
22. The polypeptide of claim 19 further comprising an immunoglobulin constant domain sequence.
23. A composition comprising an amount _ of an L-selectin ligand polypeptide of claim 19 effective in blocking the binding of a corresponding L-selectin receptor to its native ligand on an endothelial cell, in association with a non-toxic, pharmaceutically acceptable excipient.
24. The use of an L—selectin ligand polypeptide according to claim 19 in the manufacture of a medicament for the treatment of a symptom or condition associated with excessive binding of circulating leukocytes to endothelial cells.
25. The use of claim 24 wherein said polypeptide is administered in an amount effective in blocking the binding of L-selectin on a circulating leukocyte to an endothelial ligand of L-selectin.
26. The use of claim 25 further comprising the administration of an antiinflammatory or an antineoplastic drug. 10
27. An antibody immunoreactive with the protein part of an L-selectin ligand polypeptide according to claim 19.
28. A method for determining the presence of a nucleotide sequence encoding an L—se|ectin ligand polypeptide according to claim 19 comprising a) hybridizing a nucleic acid encoding the protein having the amino acid sequence shown in
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
USUNITEDSTATESOFAMERICA06/05/19916 | |||
US07/695,805 US5318890A (en) | 1991-05-06 | 1991-05-06 | Assays for inhibitors of leukocyte adhesion |
US07/834,902 US5304640A (en) | 1991-05-06 | 1992-02-13 | DNA sequence encoding a selectin ligand |
Publications (2)
Publication Number | Publication Date |
---|---|
IE83824B1 true IE83824B1 (en) | |
IE921450A1 IE921450A1 (en) | 1992-11-18 |
Family
ID=27105653
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IE145092A IE921450A1 (en) | 1991-05-06 | 1992-07-01 | Selectin ligands |
Country Status (11)
Country | Link |
---|---|
US (1) | US5484891A (en) |
EP (1) | EP0584229B1 (en) |
JP (2) | JP3859697B2 (en) |
AT (1) | ATE245696T1 (en) |
AU (1) | AU660995B2 (en) |
CA (1) | CA2108029A1 (en) |
DE (1) | DE69233136T2 (en) |
DK (1) | DK0584229T3 (en) |
ES (1) | ES2201049T3 (en) |
IE (1) | IE921450A1 (en) |
WO (1) | WO1992019735A1 (en) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5766853A (en) * | 1990-06-11 | 1998-06-16 | Nexstar Pharmaceuticals, Inc. | Method for identification of high affinity nucleic acid ligands to selectins |
US6001988A (en) * | 1990-06-11 | 1999-12-14 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands to lectins |
US5780228A (en) * | 1990-06-11 | 1998-07-14 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands to lectins |
US6280932B1 (en) * | 1990-06-11 | 2001-08-28 | Gilead Sciences, Inc. | High affinity nucleic acid ligands to lectins |
AU667813B2 (en) * | 1991-05-03 | 1996-04-18 | Rockefeller University, The | Amino-acid sequence homologies between selectins and B pertussis toxin-peptides derived therefrom antibodies thereto pharmaceutical compositions |
US5728802A (en) * | 1992-05-06 | 1998-03-17 | Affymax Technologies N.V. | Peptides and compounds that bind selectins including endothelium leukocyte adhesion molecule 1 (ELAM-1) |
US5648458A (en) * | 1992-05-06 | 1997-07-15 | Affymax Technologies N.V. | Peptides and compounds that bind to ELAM-1 |
US5643873A (en) * | 1992-05-06 | 1997-07-01 | Affymax Technologies N.V. | Peptides and compounds that bind selectins including endothelial leukocyte adhesion molecule 1 |
EP0666914B1 (en) * | 1992-10-23 | 2003-12-10 | Genetics Institute, LLC | Novel p-selectin ligand protein |
US6277975B1 (en) | 1992-10-23 | 2001-08-21 | Genetics Institute, Inc. | Fusions of P-selectin ligand protein and polynucleotides encoding same |
US5843707A (en) * | 1992-10-23 | 1998-12-01 | Genetics Institute, Inc. | Nucleic acid encoding a novel P-selectin ligand protein |
WO1994018321A1 (en) * | 1993-02-01 | 1994-08-18 | Genentech, Inc. | GLYCAM-1 (SgP50) VARIANTS |
EP0697880B1 (en) * | 1993-05-03 | 2001-08-22 | Genentech, Inc. | Inhibition of leukocyte adhesion |
US5976540A (en) * | 1993-05-17 | 1999-11-02 | T Cell Sciences, Inc. | Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions |
US5856300A (en) * | 1994-05-12 | 1999-01-05 | T Cell Sciences, Inc. | Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions |
PT730608E (en) | 1993-05-17 | 2002-09-30 | Avant Immunotherapeutics Inc | COMPOSITIONS COMPOSING CARBON HYDRATES AND PROEINS RELATED BY THE COMPLEMENT AND METHODS FOR PRODUCING AND USING THE COMPOSITION REFERENCES |
US5750508A (en) * | 1993-06-16 | 1998-05-12 | Glycomed Incorporated | Sialic acid/fucose based medicaments |
US5679321A (en) * | 1993-06-17 | 1997-10-21 | Glycomed Incorporated | Sialic acid/fucose based medicaments |
WO1995030001A2 (en) * | 1994-04-28 | 1995-11-09 | Genetics Institute, Inc. | Novel p-selectin ligand protein |
US20090118481A1 (en) * | 1995-06-07 | 2009-05-07 | Gilead Sciences, Inc. | High Affinity Nucleic Acid Ligands To Lectins |
AU725590B2 (en) * | 1995-06-07 | 2000-10-12 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands to lectins |
US6677164B1 (en) | 1995-11-21 | 2004-01-13 | Novartis Ag | Multivalent polymers, processes for their preparation, and their use for preparing biologically active compounds |
EP1053307A4 (en) * | 1998-02-11 | 2002-10-31 | Univ California | Podocalyxin like sialomucins having selectin ligand activity |
AU2003249641B2 (en) | 2002-05-16 | 2009-08-20 | Glycomimetics, Inc. | Compounds and methods for inhibiting selectin-mediated function |
US20040096396A1 (en) * | 2002-07-03 | 2004-05-20 | Glycomimetics, Inc. | Compositions and methods for diagnosis and therapy of medical conditions involving angiogenesis |
US20040219158A1 (en) * | 2003-05-02 | 2004-11-04 | Glycomimetics, Inc. | Compositions and methods for diagnosis and therapy of medical conditions involving infection with pseudomonas bacteria |
US7361644B2 (en) * | 2003-11-19 | 2008-04-22 | Glycomimetics, Inc. | Specific antagonist for both E- and P-selectins |
US20050187171A1 (en) * | 2003-11-19 | 2005-08-25 | Glycomimetics, Inc. | Glycomimetic antagonists for both E-and P-selectins |
US8201377B2 (en) * | 2004-11-05 | 2012-06-19 | Faus Group, Inc. | Flooring system having multiple alignment points |
US20090036386A1 (en) * | 2005-05-25 | 2009-02-05 | Glycomimetics, Inc | Heterobifunctional compounds for selectin inhibition |
ATE528311T1 (en) * | 2005-08-09 | 2011-10-15 | Glycomimetics Inc | GLYCOMIMETIC INHIBITORS OF PA-IL-LECTIN, PA-IIL-LECTIN OR BOTH LECTINS FROM PSEUDOMONAS |
JP5209476B2 (en) | 2005-09-02 | 2013-06-12 | グリコミメティクス, インコーポレイテッド | Heterobifunctional all-selectin inhibitor |
WO2007143052A1 (en) * | 2006-06-01 | 2007-12-13 | Glycomimetics, Inc. | Galactosides and thiodigalactosides as inhibitors of pa-il lectin from pseudomonas |
EP2074132B1 (en) | 2006-10-12 | 2013-05-15 | GlycoMimetics, Inc. | Glycomimetic replacements for hexoses and n-acetyl hexosamines |
CA2677747A1 (en) * | 2007-02-09 | 2008-08-21 | Glycomimetics, Inc. | Methods of use of glycomimetics with replacements for hexoses and n-acetyl hexosamines |
CN104198690B (en) * | 2007-06-08 | 2016-09-07 | 奎斯特诊断投资公司 | Lipoprotein analysis is carried out by differential charged-particle mobility |
US8039442B2 (en) | 2007-07-18 | 2011-10-18 | Glycomimetics, Inc. | Compounds and methods for treatment of sickle cell disease or complications associated therewith |
US8895510B2 (en) | 2008-04-08 | 2014-11-25 | Glycomimetics, Inc. | Pan-selectin inhibitor with enhanced pharmacokinetic activity |
CN102088983B (en) * | 2008-06-13 | 2013-01-30 | 糖模拟物有限公司 | Treatment of cancers of the blood using selected glycomimetic compounds |
CA2760292A1 (en) * | 2009-05-01 | 2010-11-04 | Glycomimetics, Inc. | Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors |
WO2012037034A1 (en) | 2010-09-14 | 2012-03-22 | Glycomimetics, Inc. | E-selectin antagonists |
AU2012358150B2 (en) | 2011-12-22 | 2017-07-20 | Glycomimetics, Inc. | E-selectin antagonist compounds, compositions, and methods of use |
CA2891514C (en) | 2012-12-07 | 2020-08-25 | Glycomimetics, Inc. | Compounds, compositions and methods using e-selectin antagonists for mobilization of hematopoietic cells |
CA2968391C (en) | 2014-12-03 | 2022-04-26 | Glycomimetics, Inc. | Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors |
WO2017127422A1 (en) | 2016-01-22 | 2017-07-27 | Glycomimetics, Inc. | Glycomimetic inhibitors of pa-il and pa-iil lectins |
US11291678B2 (en) | 2016-03-02 | 2022-04-05 | Glycomimetics, Inc | Methods for the treatment and/or prevention of cardiovascular disease by inhibition of E-selectin |
EP3497131B1 (en) | 2016-08-08 | 2022-03-09 | GlycoMimetics, Inc. | Combination of t-cell checkpoint inhibitors with inhibitors of e-selectin or cxcr4, or with heterobifunctional inhibitors of both e-selectin and cxcr4. |
JP7069136B2 (en) | 2016-10-07 | 2022-05-17 | グリコミメティクス, インコーポレイテッド | Extremely potent multimeric E-selectin antagonist |
US11197877B2 (en) | 2017-03-15 | 2021-12-14 | Glycomimetics. Inc. | Galactopyranosyl-cyclohexyl derivauves as E-selectin antagonists |
US11712446B2 (en) | 2017-11-30 | 2023-08-01 | Glycomimetics, Inc. | Methods of mobilizing marrow infiltrating lymphocytes and uses thereof |
EP3732186A1 (en) | 2017-12-29 | 2020-11-04 | GlycoMimetics, Inc. | Heterobifunctional inhibitors of e-selectin and galectin-3 |
CN111867601A (en) | 2018-03-05 | 2020-10-30 | 糖模拟物有限公司 | Methods for treating acute myeloid leukemia and related disorders |
US11845771B2 (en) | 2018-12-27 | 2023-12-19 | Glycomimetics, Inc. | Heterobifunctional inhibitors of E-selectin and galectin-3 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5272263A (en) * | 1989-04-28 | 1993-12-21 | Biogen, Inc. | DNA sequences encoding vascular cell adhesion molecules (VCAMS) |
-
1992
- 1992-05-06 DE DE69233136T patent/DE69233136T2/en not_active Expired - Fee Related
- 1992-05-06 AU AU19937/92A patent/AU660995B2/en not_active Ceased
- 1992-05-06 DK DK92912173T patent/DK0584229T3/en active
- 1992-05-06 JP JP51200892A patent/JP3859697B2/en not_active Expired - Fee Related
- 1992-05-06 ES ES92912173T patent/ES2201049T3/en not_active Expired - Lifetime
- 1992-05-06 CA CA002108029A patent/CA2108029A1/en not_active Abandoned
- 1992-05-06 EP EP92912173A patent/EP0584229B1/en not_active Expired - Lifetime
- 1992-05-06 WO PCT/US1992/003755 patent/WO1992019735A1/en active IP Right Grant
- 1992-05-06 AT AT92912173T patent/ATE245696T1/en not_active IP Right Cessation
- 1992-07-01 IE IE145092A patent/IE921450A1/en not_active IP Right Cessation
-
1993
- 1993-02-18 US US08/018,994 patent/US5484891A/en not_active Expired - Lifetime
-
2002
- 2002-08-06 JP JP2002228802A patent/JP3691467B2/en not_active Expired - Fee Related
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IE83824B1 (en) | A selectin ligand | |
US5652343A (en) | Method for purification of L-selectin ligands | |
AU660995B2 (en) | Glycam-1 (Sgp 50), a selectin ligand | |
JP4145356B2 (en) | P-selectin ligand protein | |
JP4237711B2 (en) | Novel P-selectin ligand protein | |
AU656934B2 (en) | Inhibition of cell adhesion protein-carbohydrate interactions | |
WO1997011971A1 (en) | Porcine cell interaction proteins | |
JP2005041882A (en) | Chimeric protein which blocks complement activation | |
AU642731B2 (en) | Mononuclear leukocyte directed endothelial adhesion molecule associated with atherosclerosis | |
WO1999043834A2 (en) | P-selectin ligand protein, including tetrameric fusion proteins | |
MCKNIGHT et al. | Murine Macrophages | |
EP0866807A1 (en) | Porcine cell interaction proteins | |
WO1994018321A1 (en) | GLYCAM-1 (SgP50) VARIANTS |